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Therapeutic protein drugs are part of an emerging new generation of pharma-
ceutical products. However, production of such drugs is expensive due to the
complex nature of many human proteins and post-translational modifications
required for physiological efficacy and pharmacokinetic activity. We have de-
veloped several tools to improve production of human-like proteins in a rela-
tively inexpensive host, Escherichia coli. First, we developed a system for moni-
toring and engineering protein solubility in the bacterial periplasm, a compart-
ment with many useful features for heterologous protein expression. Next, we
developed a system for monitoring protein-protein interactions in vivo in the
periplasm, which we can leverage for the production of novel and improved
antibodies and antibody fragments. Building upon our protein folding reporter
technology, we have developed a system for examining the effect of N-linked
glycosylation, an important post-translational modification, on protein folding
in vivo. This system allows us to (1) study the effect of glycosylation on fold-
ing of various glycoproteins from pathogenic organisms and (2) create a genetic
selection with the purpose of engineering the glycosylation pathway using the
versatile E. coli as a host. Finally, we have created a modified genome-scale
flux balance analysis model of E. coli to determine in silico metabolic factors that
affect glycosylation efficiency.
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CHAPTER 1
ENGINEERING THE PROTEIN FOLDING LANDSCAPE
Protein folding 1 - the attainment of a discrete, stable, three-dimensional struc-
ture - is the primary prerequisite for protein function. Since proteins gradually
evolve over long times with changing functions and structures, it is reasonable
to assume that protein folding presents a significant obstacle for living systems.
Moreover, the ability of microorganisms such as bacteria to reliably produce
polypeptide chains that fold into functional proteins is a cornerstone of biotech-
nology. Thus, the inability to fold recombinant proteins in vivo represents a
major bottleneck of the biotechnology enterprise [11]. To remedy this situation
will ultimately require an improved understanding of the mechanisms of pro-
tein folding and aggregation in the complex environment of the cell. This is
a formidable challenge because much of what we know regarding the protein
folding process comes from in vitro studies using a wide array of sophisticated
approaches that are difficult or impossible to implement in vivo. Furthermore,
in vitro experiments may be of limited value in predicting in vivo folding be-
havior for the same protein as it is now well established that protein folding
under physiological conditions in the presence of all other cellular constituents
differs greatly from protein folding in a test tube of aqueous buffer [59, 101].
In the intracellular environment, protein folding and solubility are governed
by the thermodynamics of folding in high concentrations of macromolecules,
interaction with folding chaperones and isomerases, susceptibility to protease
degradation, compatibility with secretory trafficking, as well as the general im-
pact of folded protein expression on the fitness of cells. For instance, while some
1Adapted with permission from Mansell TJ, Fisher AC, and DeLisa MP, ”Engineering the
Protein Folding Landscape” (2008) Current Protein and Peptide Science, 9 2, pp. 138-149
1
proteins are able to fold spontaneously in vitro without assistance from or inter-
action with other proteins, numerous others require interactions with accessory
molecules like molecular chaperones To attain a properly folded conformation
[89, 90, 99, 115, 255]. Still other proteins interact with chaperones To remain in
an unfolded state, especially those proteins which will be transported via cel-
lular translocation pathways [70]. Despite an incomplete understanding of the
complexities of intracellular protein folding, a number of recent experimental
advances have provided researchers with an unprecedented opportunity to (i)
visualize proteins in their native environment [237] and (ii) directly enhance the
folding properties of any particular protein. In the former case, imaging pro-
tein dynamics in living cells has been facilitated largely through the advent of
genetically-encoded fluorophores such as the green fluorescent protein (GFP) al-
though a number of next generation approaches have been developed recently
that correlate a protein’s dynamics with its changing structural state or activ-
ity [38]. In the latter case, modulating the folding behavior of a target protein
sequence has been accomplished by making mutations either rationally or ran-
domly to the primary structure of a protein and assaying for improved fold-
ing and/or function in living cells [151, 152, 241]. The most common targets
for such a strategy are complex heterologous proteins that are often poorly ex-
pressed in simple host organisms (e.g., expression of mammalian proteins in
Escherichia coli) [56]. However, for many proteins, especially therapeutic pro-
teins, it is typically undesirable to alter the amino acid sequence even if it results
in an improved protein as this may have severe consequences such as loss of ef-
ficacy or introduction of unexpected antigenicity. A more attractive approach is
to move away from engineering proteins one-at-a-time, and instead to exploit
our ever-increasing awareness of the factors influencing protein folding in bac-
2
teria [80, 10]. In this article, we review a number of interrelated efforts and the
methods used therein to engineer better-folding cells by re-designing the intra-
cellular landscape in a manner that universally improves the efficiency of the
folding process (see Fig.1.1).
Engineering ribosomal translation
The central dogma of molecular biology, first enunciated by Francis Crick in
1958 [47] and reiterated in 1970 [48], is represented by three major stages: repli-
cation of DNA, transcription of DNA into mRNA and translation of mRNA
into protein. The translation process is catalyzed by the ribosome, a 2.3 MDa-
complex assembly of proteins and RNA that serves as the birthplace of proteins
in the cell. Structural analysis of the entire ribosome in complex with bound tR-
NAs, mRNAs and chaperones [35, 68, 125, 205, 256] has resulted in a quantum
jump in our understanding of how the genetic code is translated into proteins.
Results of these and related studies have illuminated surprising aspects of cel-
lular protein biosynthesis, including the active participation of the ribosome in
the earliest stages of protein folding [45, 68, 96, 97, 123, 133, 147, 259]. Based
on its ability to impact the protein folding process, the ribosome and its co-
factors (tRNA, mRNA, ribosome-associated chaperones) are a prime target for
researchers seeking to develop strategies that improve the folding efficiency of
target proteins. Folding and translation rate. In living cells, there is a correla-
tion between the frequency of codon usage and the level of cognate tRNA. As
a result, translational problems such as frameshifting [195, 214], hopping [110],
or premature termination of translation [79, 84, 91, 195] are often encountered
when an mRNA contains high levels of rarely used codons (e.g., the AGA and
3
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AGG codons for arginine are the least used codons in E. coli [169]). Due to the
inherent relationship between translation rate and the folding of the nascent
polypeptide chain, rare codons can be particularly aggravating for biotechno-
logical applications where heterologous genes are expressed in a host organ-
ism whose codon bias may be incompatible with the sequence of the cloned
gene [50, 109]. This problem can often be remedied via overexpression of low-
abundance tRNAs which recognize rare codons (e.g., the Rosetta strain, see Ta-
ble 1.1) [8] or via codon optimization where rare codons are replaced with syn-
onymous codons that are preferred by the host organism [117, 127]. Indeed, rare
codons can impart dramatic changes in the timing of translation: a 6- to 9-fold
reduction in translation rate has been observed for sequences encoded with rare
codons versus the preferred codons [20, 213]. Certain organisms have exploited
this phenomenon to productively slow the kinetics of translation as a means of
influencing the folding behavior of a growing nascent polypeptide chain. For
instance, in the structural organization of complex multidomain proteins in E.
coli, protein domain boundaries are largely coded by translationally slow re-
gions on the RNA [225]. This suggests that induction of ribosome slowing or
pausing may provide a mechanism for efficient co-translational folding of indi-
vidual domains and reveals an intriguing mechanism of in vivo protein folding.
However, care must be taken when altering translation rates as the introduction
of certain synonymous codons can have a profound effect on the folding behav-
ior of both endogenous [122] and heterologous [46] proteins. One study even
demonstrated [122], that the presence of a rare synonymous polymorphism in
human P-glycoprotein (P-gp) altered its conformation and substrate specificity,
presumably by a change in the timing of co-translational folding on the ribo-
some. Based on the above findings, we speculate that while controlling the
5
speed of the ribosome via codon manipulation may cause folding problems in
some cases, it could in other cases prove to be an effective strategy for synchro-
nizing translation kinetics with the optimal folding rate of a given target pro-
tein. One intriguing candidate for ribosomal pausing is the C-terminus of the
normally periplasmic SecM protein that encodes an arrest sequence that causes
elongation cessation within the ribosome [232]. Introduction of this stall se-
quence at the C-terminus of a variety of recombinant proteins (e.g., GFP, single-
chain antibody fragments) did not result in a loss of function but rather efficient
stalling and display of functional proteins on ribosomes in vivo [44, 63]. Riboso-
mal exit tunnel. One potential region of the ribosome itself that may have the
greatest influence on the early stages of protein folding is the protein- and RNA-
lined exit tunnel, depicted in Fig. 1.2. This physical tunnel is approximately 100
long and ranges from 10-20 in diameter (large enough to accommodate an ?-
helix) and has been hypothesized to affect folding of nascent peptides in vivo
[132, 105]. In support of this hypothesis, Johnson and coworkers reported that
?-helix formation in transmembrane proteins was induced and stabilized by the
ribosome exit tunnel [252]. Further evidence comes from molecular dynamics
simulations demonstrating that translocation of a polypeptide through an exit
tunnel-like channel can affect both the kinetics and thermodynamics of nascent
polypeptide folding [45, 123, 259]. As our understanding of the exit tunnels role
in protein folding increases, it is expected that intentional alterations to the exit
tunnel proteins and/or RNA might yield substrate-optimized tunnels that favor
in vivo folding of heterologous proteins. Along these lines, we have employed
a directed evolution strategy (see Fig. (1.3)) to isolate variants of the exit tun-
nel protein L29 that may enhance the folding of GFP (Contreras-Martinez and
DeLisa, unpublished observations).
6
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TF
Figure 1.2: The ribosomal exit tunnel. This cross section of the 50S subunit of
the E. coli ribosome depicts the peptidyltransferase center (PTC, black with star),
the emerging polypeptide (black line), and notable proteins bordering the exit
tunnel (white). The bulk of the subunit is represented in grey. Peptide bond
formation occurs in the PTC and the polypeptide must pass through the narrow
(10-20 in diameter), long (100 in length) exit tunnel before emerging from the
ribosome. Proteins L23 and L29 are believed to interact with the nascent peptide
and moderate interactions with chaperones and other cytosolic proteins. Figure
adapted from Jenni and Ban [51].
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Besides its direct role in protein folding, the ribosomal exit tunnel also serves
as a docking site for molecular chaperones that engage the nascent polypeptide
as it emerges from the tunnel. Most notably, the chaperone trigger factor (TF) is
known to bind to ribosomes via contacts with the exit tunnel protein L23 and,
to a lesser extent, L29 [12, 68, 133]. From its perch on the ribosome, TF creates
a protected folding environment where nascent proteins may be shielded from
proteases and aggregation [68]. Accordingly, overexpression of TF in the cyto-
plasm of E. coli with aggregation-prone recombinant proteins, such as human
lysozyme or mouse endostatin, had marked effects on the soluble production
of these proteins [173]. Like TF, the targeting factor signal recognition parti-
cle (SRP), which interacts specifically with the signal sequence in nascent inner
membrane and periplasmic proteins, was found to interact extensively with the
L23 and L29 proteins [232]. Since many membrane proteins are secreted via
the SRP-dependent secretory pathway, we speculate that, by analogy to TF, SRP
overexpression is likely to be useful for more efficient expression of heterolo-
gous inner membrane proteins such as eukaryotic G protein-coupled receptors
(GPCRs), a class of proteins whose crystal structures remain elusive due to ex-
pression bottlenecks [158]. More recently, covalent attachment of recombinant
proteins to exit tunnel components such as L23 and TF has yielded several new
technologies including (i) a platform for soluble expression and purification of
aggregation-prone proteins [212] and (ii) targeted proteolysis for conditional in-
activation of essential proteins [95]. In addition to TF and SRP binding, the exit
tunnel also plays a key role in binding the SecM stall sequence under secretion-
defective conditions [170]. Specifically, the SecM arrest sequence interacts with
the ribosomal exit tunnel via contacts with 23S rRNA and ribosomal protein
L22 and causes elongation arrest within the ribosome [232]. This mechanism
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was recently exploited for the development of an intracellular ribosome display
technology that facilitated directed evolution of antibodies with enhanced cy-
tosolic stability [44].
Engineering protein folding in the cytoplasm
Macromolecular crowding
After emerging from the ribosome, the polypeptide enters an environment
crowded with macromolecules of protein, DNA, and RNA. One of the largest
differences between protein folding in aqueous buffer and folding in vivo is this
high concentration of macromolecules within the cell that can reach 300-400 g/L
depending on cell cycle [58, 149]. While this macromolecular crowding is be-
lieved to generally contribute to in vivo protein folding by facilitating greater
association of polypeptide chains with chaperones and thereby enhancing the
activity of molecular chaperones [58] distributed throughout the cytoplasm, it
can also be a barrier for correct folding, especially for proteins that are prone to
aggregation [219]. Without chaperones, folding is physically more challenging
in a crowded milieu although there are some proteins (e.g. apocytochrome b5)
that prefer to fold when crowding agents are added to dilute solutions in vitro,
and when expressed in vivo [29]. Since the folding phenomenon in the face
of macromolecular crowding is inconsistent, a not-so-obvious target for modi-
fying the protein folding landscape is the intracellular macromolecule concen-
tration and composition. One intriguing (and ostensibly counterintuitive) way
to modify the macromolecular concentration in bacteria for improved protein
folding is the expression of the endoribonuclease toxin MazF that specifically
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cleaves mRNAs at ACA sequences [257, 258]. The expression of this toxin leads
to quasi-dormant cells that, in spite of complete cell growth inhibition, are capa-
ble of energy metabolism and the biosynthesis of RNA and protein [218]. These
quasi-dormant cells provide a means of producing only a protein of interest, in
high-yield, in the virtual absence of background protein expression. The major
success of this feat of engineering was, following nucleotide optimization and
the noncoding mutation of all ACA sequences, the production of soluble human
eotaxin with greater than 90% purity. Intrinsic factors affecting cytoplasmic pro-
tein folding. A proteins structure is key to its function and its primary amino
acid sequence is, of course, key to its structure. Changes in amino acid sequence
can affect the function and folding properties of any given protein. With this in
mind, protein engineers have often sought to enhance a proteins folding prop-
erties by altering its primary sequence using, for instance, (i) rational design to
create more soluble peptides [194] and stability-enhanced serine proteases like
subtilisin [28] and (ii) directed evolution (see Fig. (3)) to select for super-soluble
or superfolder proteins [178]. However, a detailed discussion of how sequence-
specific changes can be implemented to yield better folding proteins is outside
the scope of this review and, instead the reader is referred to the following re-
views [151, 152, 241].
Extrinsic factors affecting cytoplasmic protein folding
In addition to engineering of the protein itself, many steps have been taken to
engineer the local environment in which protein folding occurs. For instance,
numerous studies have shown that optimal production of certain proteins is
temperature dependent [37], with many proteins responding favorably to ex-
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pression at 25◦C or 30◦C. Even lower temperatures have proven to be beneficial
for the expression of toxic and/or proteolytically sensitive proteins [166]. Two
factors that may contribute to increased expression at lower temperatures are
slower protein aggregation kinetics and diminished protease activity. Along
similar lines, Gill et al. demonstrated that chemically-induced cell condition-
ing was an effective means of dynamically altering the stress gene response in
a manner that was favorable for recombinant protein expression [81]. How-
ever, engineering the folding environment in vivo is not limited to changing
extracellular conditions. For example, alteration of a proteins immediate en-
vironment via fusion to a well-expressed partner like E. coli maltose binding
protein [196], thioredoxin [138], or glutathione-S-transferase [209] can dramat-
ically increase expression of the target protein. Alternatively, genetic engineer-
ing has been used to re-design the cytoplasmic environment in a manner that
promotes disulfide bond formation. In the cytoplasm of E. coli, the formation
of disulfide bonds is strongly disfavored by the highly reducing environment
of the cytoplasm, which is maintained by the proteins thioredoxin and glutare-
doxin [186]. Since the stability of many heterologous proteins, particularly those
of mammalian origin having multiple cysteine residues, depends on disulfide
bond formation [219], cytoplasmic production of these proteins is generally con-
fronted by misfolding, aggregation and inclusion body formation. To remedy
this situation, Beckwith and colleagues used a screen based on the activity of
an export-defective variant of the enzyme alkaline phosphatase (AP) to isolate
a strain of E. coli in which stable disulfide bonds formed in the cytoplasm [54].
Since AP requires the formation of disulfide bonds to function, mutants were
selected that recovered AP function and allowed cytoplasmic disulfide bond
formation. These mutations mapped to thioredoxin reductase, encoded by the
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trxB gene. Efforts to improve disulfide bond formation in the cytoplasm created
strains deficient in both trxB and glutathione oxidoreductase (gor) which did
improve disulfide formation but resulted in a growth defect that rendered cells
less than useful for protein expression applications. Further refinement lead
to the creation of a trxB gor ahpC* triple mutant known as FA113 that permits
formation of stable disulfide bonds in the cytoplasm and grows comparably to
wild-type [17]. Using strain FA113, successful cytoplasmic expression of oxi-
dized, biologically active tissue plasminogen activator, a complex protein con-
taining 17 disulfide bonds, was achieved [17]. A related strain, namely DR473,
that carries a genomic copy of the trxB gene under control of the arabinose-
inducible promoter pBAD, was developed to enable greater tuning of the redox
environment of the cytoplasm. These redox engineered strains (see Table 1.1 for
relevant genotypes/phenotypes) have been used extensively for the produc-
tion of proteins with multiple disulfide bonds [53, 168]. The full, detailed story
of the creation of strains with oxidizing cytoplasms can be found in a recent
review/retrospective by Jon Beckwith [13].
Molecular chaperones
The role of molecular chaperones including DnaK, DnaJ, GrpE, GroEL and
GroES as well as their mechanism of action was extensively reviewed by Houry
in 2001 [98] and thus will not be covered in detail here. Briefly, chaperones in
the cytoplasm can serve three purposes: (i) holding chaperones (e.g., IbpB) that
retain partially folded proteins until the arrival of folding chaperones and help
shield their substrates from proteolysis; (ii) folding chaperones (e.g., DnaK and
GroEL) that rely on ATP to drive either folding in the case of partially folded
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substrates or unfolding in the case of misfolded substrates; and (iii) unfolding
chaperones (e.g., ClpA and ClpB) that help to solubilize proteins that have ag-
gregated and/or unfold them in preparation for refolding (by a folding chap-
erone) or degradation (by a protease). Following their initial interaction with
trigger factor (see above), nascent chains are released from the E. coli ribosome
and can either attain folded conformations unassisted or might require the ac-
tivity of additional molecular chaperone systems. At an early stage of folding,
unfolded polypeptide segments are typically recognized by the Hsp70 chaper-
one system, which is comprised of DnaK, DnaJ and GrpE [30]. The chaperone
system formed by GroEL and GroES typically becomes involved at a later stage
in the folding process. This system is arguably one of the most significant chap-
erone complexes in E. coli as evidenced by the fact that it is the only such system
that is essential under all conditions of growth [64] and by the extraordinary
number of proteins that interact with GroEL/GroES in their lifetime [99, 115].
Many chaperones, including GroEL/GroES, exhibit broad substrate specificity
for a diverse range of newly synthesized proteins [99, 115], including many het-
erologous proteins that may not normally encounter the chaperone(s) in nature.
As a result, overexpression of molecular chaperones has proven to be a useful
strategy for improving cytoplasmic folding and solubility of a wide of array of
protein substrates that bear little resemblance to one another with respect to
sequence, structure and function [86, 140, 172, 173, 226, 173, 227]. However,
despite this success, chaperone overexpression strategies frequently require te-
dious trial-and-error analysis to optimize the choice and expression level of the
chaperone system(s) for each new target protein under investigation. This in-
herent lack of specificity for a given protein effectively limits the folding effi-
ciency of a chaperone towards a specific target [62]. To address this limitation,
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Figure 1.3: Schematic of the directed evolution process. By following an itera-
tive cycle of DNA mutagenesis to introduce diversity and selection to identify
unique clones with the desired phenotype, researchers can obtain proteins (or
protein complexes) with improved or even vastly different functions.
Weissman and coworkers used a directed evolution strategy (see Fig. (3)) to
create a variant of GroEL/S that dramatically enhanced folding of a single sub-
strate [243]. This acquired substrate specificity came at the expense of the chap-
erone systems generality as manifested by the inability of the GroEL/S variants
to fold a variety of their natural substrates. Nonetheless, this groundbreaking
study was the first example in what will undoubtedly become a growing pur-
suit of researchers in the future: chaperone engineering.
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Cytoplasmic protein folding reporters
The development of tailor-made chaperones specific for certain substrates, es-
pecially by directed evolution, necessarily requires the engineering of robust
genetic screens or selections to identify factors that effect folding of the target
substrate. This can be particularly challenging since relatively few substrates,
especially those which are foreign to host, are screenable. Thus, a suitable assay
for proper folding is essential for substrates such as these as well as for the iden-
tification of new engineer-able targets in the protein folding landscape. Fortu-
nately, a variety of genetic tools have been developed to identify properly folded
proteins in the bacterial cytoplasm. In general, these assays involve construction
of a genetic fusion between an analyte protein-of-interest and a reporter protein.
The underlying premise is that the folding behavior of the analyte protein will
directly influence the reporter protein such that the reporter activity is represen-
tative of the analytes folding status. For example, Waldo and colleagues fused
green fluorescent protein (GFP) to the C-terminus of a wide array of test pro-
teins and found that bacterial cell fluorescence correlated positively with the
relative solubility of the analyte partner [240]. A number of similar approaches
have been developed using either chloramphenicol acetyltransferase [156], the
Gal11P-activation domain [6], the RNAse-A S-peptide [113] or dihydrofolate re-
ductase [146] as the reporter protein in the fusion construct; sometimes even in
combination [104]. More recently, next-generation protein folding assays have
been developed that take advantage of the structural complementation of split
protein fragments derived from GFP [34, 33], β-galactosidase [250], and dihy-
drofolate reductase (DHFR) [180] instead of full-length reporter proteins. The
advantage of these reporters, split or otherwise, is that each is amenable to
high-throughput experimentation thereby enabling combinatorial strategies for
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evolving better folding proteins or cells [152, 151, 241]. It should be noted that
an implicit assumption in assays involving protein fusions is that the analyte
protein must affect the folding and function of the reporter protein, but not vice
versa. Unfortunately, this is not always the case as reporter proteins can often
attain an active conformation even when the analyte to which they are fused
is insoluble [184] or aggregated [230]. Thus, care must be taken when inter-
preting results from experiments where these approaches have been employed
to characterize or engineer the protein folding machinery in cells. An alterna-
tive method for assaying protein folding was recently developed that does not
rely on the expression of artificial protein chimeras, but rather on the genetic
response of the cell to misfolded proteins [130]. Cells have evolved exquisite
methods for exerting protein folding quality control including, for example, the
upregulation of many chaperones and proteases in response to misfolded or
aggregated protein. Thus, simple cloning of a reporter gene (e.g., lacZ) under
the control of a promoter for such an upregulated chaperone or protease results
in a biosensor that responds to protein misfolding. To date, genetic elements
that have been used to successfully assay protein folding in this manner include
the promoter region of the small heat shock protein ibpAB fused to lacZ [141]
and the promoters from ibpAB and fxsA linked in tandem (ibpfxs) upstream
of the luciferase reporter gene, lucA [130]. While this promoter trap system
should clearly be useful for evolving protein sequences directly, it may be quite
challenging to explore the effect of cellular factors, especially heat shock chap-
erones, that may themselves activate the promoter. In addition, it is not clear
if such a system will be responsive to a broad spectrum of different protein
structures and misfolding events. A final drawback is the fact that productive
folding results in the absence of any signal, which may prove problematic in
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library screening experiments where improved folding is the desired outcome.
Recently, we developed a protein folding selection that relies on both a fusion
to a reporter protein and the use of cellular folding quality control [71]. The ba-
sis for this assay is the observation that protein transport through the bacterial
twin-arginine translocation (Tat) pathway depends on correct folding and solu-
bility of the substrate protein prior to transport [53]. In this system, a test pro-
tein is expressed as a sandwich fusion between an N-terminal Tat signal peptide
and a C-terminal TEM1β-lactamase (Bla) reporter protein. Bla confers antibiotic
resistance and is only effective when present in the periplasm. Viability of E.
coli cells on antibiotic selective media expressing tripartite chimeras was shown
to dependent on the solubility of the test protein. Thus, by exploiting a novel
cellular folding quality control mechanism as well as the activity of a reporter
enzyme that is amenable to high-throughput selections, we expect this reporter
assay will be quite useful for identifying and engineering cytoplasmic factors
that modulate the protein folding landscape.
Engineering membrane transport machinery
Not all cellular proteins, however, are destined to remain at their site of syn-
thesis in the cytoplasm; approximately 20% of the proteome is secreted across
the cytoplasmic membrane [188]. In fact, one way in which bacteria handle pro-
teins that are incapable of folding in the cytoplasm is by simple export to allow
folding in a different cellular compartment, such as the inner membrane or the
periplasm. Proteins bound for transport usually contain an N-terminal signal
peptide that promotes interactions with general and pathway-specific chaper-
ones and also directs the protein to interact with the translocation machinery
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(for a review, see [70]). Most proteins in E. coli are transported via the general
secretory (Sec) pathway [188], although several other functionally distinct path-
ways for inner membrane transit have been identified that provide intriguing
targets for exploiting the cellular protein folding landscape.
Sec-dependent transport
The bulk of protein transport across the inner membrane of bacteria (and also
the cell wall of Gram-positive bacteria) occurs via the Sec secretion pathway
[188]. This pathway identifies secretion substrates by cleavable N-terminal pep-
tide extensions, known as signal peptides, which target a protein substrate for
transport. Proteins traverse the membrane though the Sec translocon, a com-
plex of three integral membrane proteins (SecY, SecE and SecG) which form
a funnel structure that constricts to a ring of 5-8 in diameter [235]. As a re-
sult of this narrow conduit, proteins transported through the SecYEG translo-
con remain largely unfolded, possibly resembling a random coil, and effectively
ratchet their way through the pore in a process requiring SecA-mediated ATP
hydrolysis [198, 217]. In contrast, proteins that have adopted a kinetically stable,
folded conformation are precluded from transport via the Sec pathway [189].
For a subset of native Sec-targeted proteins, the dedicated molecular chaperone
SecB helps to maintain the substrate in an extended, export-competent confor-
mation. It is particularly noteworthy that protein secretion for biotechnology
purposes has relied almost exclusively on the Sec pathway. The significance of
the Sec pathway is highlighted by the very extensive literature covering var-
ious leader peptides useful for recombinant protein expression as well as by
the enterprise encompassed by technologies for combinatorial library screening
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of proteins and peptides such as yeast surface display [19] (Invitrogen Corpo-
ration) and phage display [210] (Dyax Corporation). However, the fact that
polypeptides secreted by Sec must be largely unfolded prior to transport has
hindered its use for certain applications. Fortuitously, several groups have
made use of prl suppressor mutants (that map in several sec genes [61]) for im-
proved Sec-dependent expression of recombinant proteins [154, 181, 193], even
though these mutants were not originally isolated for such biotechnological pur-
poses. Prl suppressors are known to allow significant export of substrates with
an array of defective, or even deleted, signal peptides [54, 75, 187]. This lack of
allele specificity has lead to the suggestion that the prl mutations broaden the
selectivity of the translocase [61] and, as a result, promote increased export ef-
ficiency of Sec-targeted heterologous proteins [154, 181, 193]. Another effective
strategy for improving Sec transport efficiency is the overexpression of SecB,
which can markedly increase the quantity of human recombinant proteins lo-
calized in the E. coli periplasmic space [15].
SRP-dependent transport
In addition to SecB-dependent transport, E. coli cells also possess an SRP-
dependent pathway for targeting to the SecYEG translocon [150, 234]. Recog-
nition of the N-terminal signal peptide by the SRP induces a change in the ri-
bosome that promotes interaction with the SRP-receptor (SR) FtsY and targets
the SRP/SR/ribosome complex to SecYEG. A key aspect of the SRP pathway is
that substrate proteins are transported into or across the inner membrane simul-
taneously with translation, thereby ensuring that secondary structures are not
formed in the cytoplasm and eliminating the inhibitory effect of protein fold-
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ing on export. Thus, in addition to translocating plasma membrane proteins
such as the lactose permease [150], the bacterial SRP pathway is also respon-
sible for export of certain soluble periplasmic proteins that fold rapidly in the
cytoplasm and thus require co-translational export [100]. It should be noted that
while SRP-dependent transport utilizes the SecYEG translocon, some evidence
suggests that it may also use the SecA ATPase to propel the nascent polypep-
tide across the membrane [199]. Based on these observations, the SRP pathway
should eventually prove to be a useful mechanism for efficient heterologous
expression of notoriously difficult membrane proteins or very stable and fast-
folding non-membrane proteins. Along these lines, a recent study by Plckthun
and coworkers demonstrated that the display efficiency of a fast-folding pro-
tein on filamentous phage could be improved up to 700-fold simply by replac-
ing Sec- with SRP-dependent signal peptides [215]. For expression of membrane
proteins, it may prove useful to combine SRP targeting with an E. coli host strain
such as C41(DE3) or C43(DE3) (see Table 1.1) that has been engineered for high-
level expression of certain membrane proteins [163].
Tat-dependent transport
The bacterial Tat pathway is a Sec-independent mode of inner membrane trans-
port that is perhaps best known for its remarkable ability to transport proteins
that have undergone folding prior to translocation (for a recent review of the Tat
system, see [139]). While many of the mechanistic details remain a mystery, our
recent studies have revealed the existence of folding quality control mechanism
that governs the transport of synthetic Tat substrate proteins of both prokary-
otic and eukaryotic origin [53, 71, 118]. As folding quality control is a crucial
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aspect of protein expression and engineering, the Tat system should emerge as
an ideal platform for numerous biotechnology applications. Already it has been
used in E. coli for expressing recombinant therapeutics such as antibodies and
human tissue plasminogen activator [53, 118, 192], screening and engineering
both protein solubility [71] and protein-protein interactions [216, 244] and dis-
playing proteins on phage [177, 224]. A current drawback of the Tat system is its
relatively low transport efficiency, however, identification of optimized signal
peptides [52, 231] as well as factors (e.g., phage shock protein A, DnaK/DnaJ)
whose overexpression increases translocation efficiency [51, 182] should help to
alleviate this bottleneck.
Engineering protein folding in the periplasmic space
General properties of the periplasm. The periplasmic environment differs in
many ways from that of the cytoplasm. First, the protein concentration is much
lower than that of the cytoplasm, so molecular crowding effects are likely not
as pronounced. However, macromolecular crowding has been shown to affect
the folding properties of certain proteins in this compartment compared to in
dilute solution [160]. Second, the environment of the periplasm is much more
susceptible to the conditions in the extracellular environment such as pH, tem-
perature, and concentration gradients of small molecules [165]. For these rea-
sons, purification of proteins from the periplasm is less complex than purifi-
cation from whole cell extracts, and methods whereby proteins are extracted
from the periplasm without whole cell lysis have been used extensively in the
literature for many years [171]. Third, the lack of a significant ATP concentra-
tion in the periplasm precludes classical chaperone activity (which entails ATP-
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driven folding). Fourth, the oxidation-reduction potential of the periplasm is
such that disulfide bonds can form readily in proteins containing multiple cys-
teine residues. Such bonds generally increase the stability of proteins, thus the
formation of disulfides is a critical step along the folding pathway of many na-
tive and non-native proteins expressed in the E. coli periplasm.
Engineering the redox environment of the periplasm.
Periplasmic disulfide bond formation is catalyzed by a family of protein disul-
fide isomerases (PDIs), all of which belong to the thioredoxin superfamily. The
most notable of these, DsbA, is oxidized by its membrane-bound partner, DsbB,
and uses this oxidation potential to catalyze the formation of disulfide bonds
(the reader is referred to [107, 165] for a more detailed review of the mechanism
of disulfide bond formation in the periplasm). Given that disulfide bond forma-
tion can greatly affect folding and stability of proteins and also that eukaryotic
proteins with therapeutic potential frequently have a high cysteine content, it is
not surprising that strains of E. coli have been engineered that allow exquisite
control of disulfide bond formation in the periplasm. For instance, overexpres-
sion of PDI family members such as E. coli DsbA and DsbC has proven to be a
reliable means of improving the folding yield of proteins with multiple disul-
fide bonds [106, 136]. Alternatively, introduction of a dsbA::kan allele into strain
DR473 (resulting in strain DRA, see Table 1.1) resulted in a strain that exhibited
an inverted redox pattern (i.e., oxidizing cytoplasm, reducing periplasm) when
glucose was added to repress trxB expression and a dsbA phenotype (reducing
cytoplasm, reducing periplasm) when arabinose was added to induce trxB [53].
Thus, the combination of strains DR473 and DRA provides researchers with a
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Table 1.1: Engineered E. coli strains with altered folding environments
Strain Name Genotype Phenotype Reference or
source
DHB4 MC1000 phoR ∆(phoA)
PvuII ∆(malF)3 F’ lacIq
ZYA pro
Reducing cytoplasm Beckwith lab
FA113 DHB4 trxB::kan gor552
Tn10Tet ahpC*
Oxidizing cytoplasm [17]
DR473 DHB4 ∆trxB gor552
Tn10Tet ahpC* Tn10Cm
(araC Para-trxB)
Arabinose-inducible oxi-
dizing cytoplasm
Beckwith lab
DHA DHB4 dsbA::kan Reducing periplasm [53]
DRA DR473 dsbA::kan Arabinose-inducible ox-
idizing cytoplasm and
reducing periplasm
[53]
BL21 B F- ompT hsdSβ (rβ-mβ-)
gal dcm
OmpT and Lon protease-
deficient
Novagen
BL21(DE3) BL21 carrying the DE3
lambda lysogen
As BL21 with T7 poly-
merase for pET vector ex-
pression
Novagen
Rosetta BL21 + pRARE As BL21 with plasmid sup-
plying tRNAs for seven
rare codons (AUA, AGG,
AGA, CUA, CCC, CGG,
and GGA)
Novagen
C41(DE3),
C43(DE3)
BL21(DE3) supp As BL21(DE3) with un-
known suppressor muta-
tions that permit growth
of cells following induc-
tion of certain toxic (e.g.,
membrane) proteins
[163]
HM130 KS272 (wild type) degP ptr
ompT tsp eda
Deficient in all cell enve-
lope proteases
[161]
powerful genetic system for toggling the redox state of both the cytoplasm and
the periplasm To observe and optimize folding of proteins in both of the bacte-
rial compartments.
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Chaperone activity in the periplasm.
Since the periplasm is not enriched in ATP like the cytoplasm [11], the exis-
tence of ATP-mediated chaperone systems in the periplasm is unlikely. Using
a screen based on the genetic response to protein misfolding in the periplasm,
Raina and coworkers identified three proteins (SurA, FkpA and Skp) that func-
tion as periplasmic folding catalysts [106]. Shortly thereafter, Bothmann and
Plckthun employed a clever strategy based on phage display of a single-chain
antibody fragment (scFv) that tended to aggregate in the periplasm to screen
an E. coli genomic library for factors that could enhance scFv folding in the
periplasm and independently identified Skp [22]. The FkpA and SurA pro-
teins are peptido-prolyl cis/trans isomerases (PPIases) that contribute to fold-
ing of unfolded intermediates by stabilizing the isomerization of prolines in the
polypeptide chain. In addition, FkpA has a chaperone activity independent of
its PPIase activity [4]. Skp has been characterized as a molecular chaperone that
interacts with unfolded proteins as they emerge in the periplasm from the Sec
translocation machinery [106] and appears to make the broadest contribution to
protein folding in the periplasmic space. As with many of the molecular chaper-
ones discussed so far, overexpression of these three proteins has lead to greater
expression and in some cases, reduced aggregation and formation of inclusion
bodies in the periplasm [22, 23, 92]. In addition to periplasmic chaperone over-
expression, Georgiou and coworkers have recently explored the notion of chap-
erone engineering in the periplasm. One such approach explored directed evo-
lution of DsbC to improve its foldase and/or isomerization activity towards
a complex, multidisulfide substrate protein that was poorly expressed in the
periplasm [137]. A key aspect of this study was the development of a phage
display assay linking the genotype of the foldase (encoded on a phagemid) to
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the phenotype of the target substrate (displayed as a fusion to pIII on the head
of the phage). Improved substrate folding was then assayed by the ability of
the substrate to bind to a surface-immobilized ligand. Thus, an obvious limita-
tion of this method is that it can only be used to screen for chaperones whose
substrate proteins exhibit activities (i.e., ligand binding or fluorescence) that are
amenable to high-throughput assays. A second approach employed a rational
design strategy to engineer DsbA-DsbC chimeras that could restore protein ox-
idation in a dsbA background and also fully substitute for DsbC in disulfide-
bond rearrangement [204]. Remarkably, several of the engineered chimeras
could fulfill both of these functions, acting as a single catalyst for both disulfide-
bond formation and rearrangement.
Periplasmic protein folding reporters.
Since periplasmic expression is favorable for many proteins, especially those re-
quiring the formation of disulfide bonds (including nearly all antibodies and
fragments derived thereof), a useful addition to the protein engineers toolkit
would be a reliable reporter of protein folding in the periplasm. A system to
report periplasmic folding could conceivably identify new factors that affect
protein folding in trans (e.g., chaperones) in a manner that does not depend on
the activity of the target protein [22]. To our knowledge, however, there are cur-
rently no general folding reporters of this type reported in the literature. One
possible factor contributing to this dearth of periplasmic folding reporters is the
apparently unreliable nature of certain reporter enzymes. For instance, Ari and
coworkers created fusions between several reporter enzymes and soluble and
insoluble variants of the E. coli maltose binding protein to study the relation-
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ship between periplasmic protein folding and aggregation [3]. These authors
suspected that reporter enzymes fused C-terminally to the aggregation-prone
MBP variant, known as MalE31, would be incorporated into inclusion bodies
and therefore be inactive. Upon testing these fusions, they observed that en-
zymes fused to MalE31 accumulated in the insoluble fraction but unexpectedly
retained their catalytic activities. Based on this observation, they concluded
that reporter enzymes were not a reliable indicator of protein solubility in the
periplasm. Another possible factor contributing to the lack of periplasmic fold-
ing reporters is the inability of GFP, one of the most commonly used reporter
proteins, to attain an active fluorescent conformation when transported to the
periplasm via the Sec machinery [65]. Interestingly, when exported through the
Sec pathway, GFP is detected in the soluble fraction of cell lysate, yet fails to
form the fluorescent chromophore for reasons that are unclear. Recently, Soren-
son et al. reported that the use of co-translational translocation allowed an engi-
neered variant known as superfolder GFP to attain fluorescence in the periplas-
mic space [212]. Superfolder GFP has been used in the past as a folding enhancer
to proteins, but given its highly structured and stable nature, it is still unclear
whether sfGFP could function as a reporter of protein folding. In any case, the
development of a protein folding reporter for the periplasm would contribute
greatly to our understanding of the complexities of the periplasmic folding envi-
ronment, and could be instrumental in isolating additional yet-to-be identified
factors that contribute to better periplasmic expression of recombinant proteins.
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Engineering proteolysis
The last stage in the life of a protein is proteolytic degradation into constituent
amino acids (for a complete review of proteolysis in E. coli see [85]). Proteases
are ubiquitous throughout the cell and are essential to cellular quality control.
However, they can be troublesome during overexpression of recombinant pro-
teins, especially if the target protein is prone to aberrant folding. To tackle this
issue, Meerman and Georgiou constructed a family of 25 isogenic strains defi-
cient in all known cell envelope proteases including DegP, Protease III, Tsp(Prc),
and OmpT to select suitable hosts based on the optimum reduction in protease
activity [161]. The genotype of HM130, one of the most effective strains rela-
tive to its growth rate, is listed in Table 1.1. Similarly, one of the most popular
strains for recombinant protein expression is BL21, a derivative of the E. coli
B strain that is deficient in the cytoplasmic protease Lon and the periplasmic
OmpT protease (see Table 1.1). In contrast to its negative effect on protein ex-
pression, intracellular proteolysis can also be productively harnessed for a num-
ber of different purposes. For instance, Sauer and colleagues have designed a
series of modified SsrA degradation tags that have varying affinities for the pro-
tease ClpXP [159]. Insertion of these tags into cellular proteins enables synthetic
toggling of the tagged proteins degradation rate. In another example, the same
SsrA degradation tag was used to ensure exclusive localization of Tat-targeted
GFP solely to the periplasm as non-transported GFP was efficiently degraded
in the cytoplasm by ClpXP [52]. Finally, proteases have also been the focus of
directed evolution studies in which the reactivity of the protease is tailored for
novel substrates, while simultaneously excluding reactivity toward undesired
substrates. Specifically, screening of a large library of random mutants of the E.
coli endopeptidase OmpT resulted in the isolation of a variant that cleaved an
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Ala-Arg peptide bond instead of the Arg-Arg bond initially preferred by the en-
zyme with a greater than 3x106-fold selectivity of Ala-Arg over Arg-Arg [236].
Introduction to bacterial N-linked glycosylation
Protein glycosylation is a post-translational modification made to proteins
wherein sugars (e.g. glucose, mannose, galactose, etc.) are covalently linked
to proteins. In eukaryotes, this process occurs in the endoplasmic reticulum
(ER) and Golgi bodies before the mature protein is released into the cytoplasm
[94]. Two types of protein glycosylation exist: N-linked and O-linked. O-linked
glycosylation, in which carbohydrate groups are transferred to serine or threo-
nine residues in the Golgi, is GCSF folding. N-linked glycosylation, however,
has been shown to be very important to many protein functions and properties
[251].
N-linked protein glycosylation involves the attachment of oligosaccharide
groups to asparagine residues of nascent polypeptides. In yeast and higher eu-
karyotes, a conserved sequence of Asn-X-Ser/Thr, where X is any amino acid
but proline, is the consensus sequence for N-linked glycosylation. Glycosyla-
tion first occurs in the ER, where the oligosaccharide is attached to the nascent
polypeptide before it adopts a folded conformation [93]. A core oligosaccha-
ride common to all eukaryotes is attached in the ER and removal and addition
of different monosaccharides in the Golgi varies from organism to organism.
For example, the most common yeast glycoform is mannose-rich, while the
human glycoform incorporates sugars like galactose and N-acetylneuraminic
acid [251]. Glycosylation has been shown in many cases to enhance folding
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of glycoproteins [103]. In fact, it has been speculated that the addition of N-
glycans has been an essential factor that has allowed eukaryotes to express high
amounts of complex proteins that are well-folded [93]. Many proteins that are
naturally glycosylated will express poorly or not at all in the absence of gly-
cosylation [251]. Until the mid-1990s, it was widely believed that protein gly-
cosylation was only present in eukaryotes [14]. Evidence of N-linked protein
glycosylation in the genome of the pathogenic bacterium Campylobacter jejuni
was found in 1999 [222] and the presence of glycosylated proteins in Campy-
lobacter was demonstrated by Linton and colleagues in 2002 [144]. Not long
after, the so-called pgl (protein glycosylation) genetic locus of C. jejuni was suc-
cessfully transferred into E. coli, and it was shown that E. coli cells were capable
of glycosylating proteins using the glycosylation machinery of C. jejuni [239].
In addition, the structure of the heptasaccharide was revealed by NMR spec-
troscopy to be GalNAc-α1,4- GalNAc-α1,4-[Glcβ1,3]GalNAc-α1,4-GalNAc-α1,4-
GalNAc-α1,3-Bac-β1,N-Asn, where Bac is bacillosamine, 2,4-diacetamido-2,4,6-
trideoxyglucose attached by the engineered E. coli was found to be identical to
that of C. jejuni [145]. In 2006, each gene in the 17-kb pgl locus was individu-
ally characterized by Kelly and colleagues [114]. The locus consists of 13 genes,
shown in Figure 4.1, most of the products of which participate in glycosylation.
The process proceeds via 5 general steps: (1) saccharide and sugar-nucleotide
biosynthesis in the cytoplasm, (2) attachment of the base sugar (bacillosamine)
to lipid precursors on the membrane, (3) transfer of sugars to the glycan on
the membrane, (4) ”flipping” of the glycan from the cytoplasmic surface to the
periplasmic surface of the inner membrane, and (5) transfer of the oligosaccha-
ride to the asparagine residue at the glycosylation site of the protein.
The laboratory of Markus Aebi (Institute of Microbiology, ETH Zurich,
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Switzerland) has pioneered the functional study of the C. jejuni machinery in
E. coli. Discoveries from this group include the requirement of the D/E-X1-N-
X2-S/T, (where X1 and X2, are any amino acid except proline) glycosylation con-
sensus sequence [129, 174], which is more specific than the classical eukaryotic
acceptor sequence of N-X-S/T. Additionally, protein folding studies on bovine
ribonuclease A in this group have concluded that the oligosyltransferase PglB
can glycosylate proteins after they have attained a folded structure, but glycosy-
lation is much more efficient when the substrate protein remains unfolded [128].
Also, it was discovered that PglB has relaxed substrate specificity to glycans,
as it was shown to successfully attach the O antigen of E. coli to protein[67].
This relaxed specificity for glycan was supported by the in vitro experiments
of Glover and colleagues with various undecaprenyl-linked disaccharides [82].
While PglB has been shown to have relaxed specificity, it is unknown if it is capable of
attaching eukaryotic- and human-like glycans to proteins.
Conclusions and future directions
From translation of a nascent polypeptide to its eventual folding, researchers
have made considerable advances in the study and engineering of cellular envi-
ronments with respect to protein folding. Our analysis of efforts to modify the
protein folding landscape has shown that strategies for better folding of recom-
binant proteins are being pursued in cytoplasmic and extracytoplasmic com-
partments of the cell, including the inner membrane, and periplasm. Despite
the production of disulfide-bonded proteins in the cytoplasm, the periplasm is
still the optimal location for folding and expression of complex proteins. This
notion is only strengthened by the recent demonstrations that fully functional
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immunoglobulin G (IgG) molecules can be expressed [208] and engineered [157]
in the periplasm of E. coli. In addition, the discovery of a bacterial system of N-
linked protein glycosylation in the pathogenic bacterium Campylobacter jejuni
and its functional transfer into E. coli [239] is especially encouraging. In this
system, the bacterial oligosaccharide is produced in the cytoplasm, but trans-
fer of the sugar group onto protein occurs in the periplasm. Thus, with con-
tinued advances in the engineering of translation, folding, secretion and post-
translational modification machinery in E. coli, it may not be long before biosyn-
thesis of (nearly) authentic human glycoproteins in this simple host is routine
practice.
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CHAPTER 2
A RAPID PROTEIN FOLDING ASSAY THE BACTERIAL PERIPLASM
Introduction
1Since the inception of recombinant DNA technology, maximizing the solubility
of heterologous proteins in Escherichia coli has been a principal goal of modern
biotechnology[11, 219, 80]. Despite the numerous advances in this area over the
past three decades, high-level expression of correctly folded, soluble proteins for
laboratory and preparative purposes remains a significant challenge. Indeed,
following their expression in the cytoplasm of E. coli, many recombinant pro-
teins of prokaryotic and eukaryotic origin are prone to misfolding[56, 148, 26]
and are subsequently degraded by cellular proteases[9, 228] or deposited into
inactive inclusion bodies[24, 238]. Protein misfolding in the cytoplasm can
be a consequence of the relative crowdedness of this compartment where
macromolecule concentration can reach 300-400 mg/ml[58]. In addition, post-
translational processing steps such as disulfide bond formation[107] or N-linked
glycosylation,[248] which are often required for correct folding, are absent from
the cytoplasm of wildtype E. coli cells. The periplasm in E. coli, on the other
hand, is often the preferred compartment for protein expression because it: (1)
contains significantly fewer proteins, particularly proteases, compared to the
cytoplasm; (2) houses a network of redox enzymes that catalyze the formation
and isomerization of disulfide bonds; and (3) permits N-linked glycosylation
in Campylobacter jejuni[248] and E. coli[239]. Consequently, periplasmic proteins
are often easier to isolate, less prone to crowding-induced aggregation and/or
1Adapted with permission from Mansell TJ, Linderman SW, Fisher AC, and DeLisa MP, ”A
rapid protein folding assay the bacterial periplasm” (2010) Protein Science, 19 5, pp. 1079-1090
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proteolytic degradation and more efficiently folded compared to their cytoplas-
mic counterparts. However, even though the significance of the periplasm for
protein expression is firmly established[165, 80], there are currently no genetic
reporter assays for monitoring protein folding in this subcellular compartment.
In stark contrast, numerous folding reporter systems have been developed for
detecting correctly folded, soluble proteins in the cytoplasm of living E. coli
cells[102, 156, 240, 250, 34, 71, 40]. These approaches commonly rely on a genetic
fusion between a protein-of-interest (POI) and a reporter protein whose specific
phenotype is independent of the POIs function[241]. In this scenario, when the
POI folds into a soluble conformation, the reporter to which it is fused is func-
tional. In contrast, when the POI misfolds or aggregates, the fused reporter
is inactive and a null phenotype is observed. Another typical feature of these
approaches is that they can be employed even when structural or functional in-
formation about the target is lacking. Perhaps the most useful aspect of these
assays is that they can be combined with well-established methods for creating
protein diversity libraries to screen or select for soluble variants of recalcitrant
proteins[73, 71, 179, 240, 40, 33] with only one exception reported so far[184].
Hence, a screen or selection for monitoring protein folding in the bacterial
periplasm would be a desirable accomplishment, but to date has been met with
technical difficulties[3]. In this study, we developed an activity-independent se-
lection strategy that reliably reports the ”folding robustness” of POIs expressed
in the periplasm. The term folding robustness is used here to denote both the
chemical solubility related to correct folding of the POI and the avoidance of ag-
gregation or degradation. The assay is based on a tripartite fusion between: (1)
an N-terminal signal peptide from E. coli DsbA (ssDsbA), which has previously
been shown to direct proteins through the bacterial signal recognition particle
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(SRP)-dependent translocation pathway[199], (2) the POI, and (3) a C-terminal
fusion of mature TEM-1β-lactamase (Bla). We chose the SRP pathway because of
its unique ability to perform co-translational export[150, 234] whereby nascent
polypeptides bearing N-terminal SRP signals are directly translated across the
inner membrane by a ribosome-translocon complex[185]. As a result, SRP-
exported proteins are expected to experience little or no residence time in the
cytoplasm, thus ensuring that protein folding takes place predominantly in the
periplasmic space. Indeed, we observed that the antibiotic resistance of cells
expressing engineered ssDsbA-POI-Bla chimeras correlated with the periplas-
mic folding behavior of the POI. Thus, simple selection onβ-lactam antibiotics
such as ampicillin (Amp) enabled discrimination between folded and misfolded
conformations of POIs, even when (i) structural and functional information and
(ii) activity assays for the POIs were lacking. The method was also capable of
evaluating trans-acting factors that influence protein folding in the periplasm
such as disulfide bond formation enzymes and molecular chaperones. Finally,
the potential of the assay for improving periplasmic protein folding and sol-
ubility was demonstrated using a directed evolution strategy. Taken together,
these results reveal our periplasmic protein-folding assay to be a powerful new
experimental tool for elucidating the factors that affect the folding of proteins in
this important biological compartment.
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Figure 2.1: Schematic of SRP-mediated periplasmic folding reporter. (a) The
DsbA signal peptide enables co-translational translocation across the cytoplas-
mic membrane via the SRP-dependent pathway. Nascent polypeptides enter
the periplasm where they fold properly, conferring Amp resistance to cells, or
misfold, leading to eventual aggregation and/or proteolysis. (b) Fusion proteins
created in this study contained an N-terminal DsbA signal peptide (ssDsbA) fol-
lowed by a POI and a C-terminal selectable marker (TEM-1 Bla). Short linkers
sequences (SR, VDGS) were created at the junctions.
Results
An engineered assay for folding and solubility in the periplasm.
To create a protein folding assay for the periplasm, we constructed a plas-
mid called pDMB that permitted expression of any POI as a sandwich fu-
sion between an N-terminal SRP-dependent export signal (ssDsbA) and a C-
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terminal reporter enzyme (Bla). Consistent with the logic underlying fusion-
based folding reporters for the cytoplasm[156, 240, 250, 34], we reasoned that
productive folding of the downstream Bla protein domain and consequent
resistance toβ-lactam antibiotics is directly related to the folding competence
(avoidance of aggregation and inclusion body formation) of the upstream POI.
Thus, correctly folded, soluble proteins would be expected to confer Amp re-
sistance to E. coli cells and provide a selectable phenotype for periplasmic
protein folding (Fig. 2.1). We chose the ssDsbA signal peptide because it is
known to direct co-translational export of heterologous proteins through the
SRP pathway[199, 215] and thus should effectively partition ssDsbA-POI-Bla
fusions to the periplasm with little to no residence time in the cytoplasm. In
this study, 32 different POIs were cloned into pDMB and characterized based
on their resistance to Amp as described below.
Monitoring DsbA-dependent folding of enzymes and antibodies in the
periplasm.
As proof-of-concept, we first investigated whether our assay could report the
folding behavior of E. coli alkaline phosphatase (PhoA). We chose PhoA be-
cause, like many other extracytoplasmic proteins, its correctly folded, catalyt-
ically active conformation is dependent upon two disulfide bonds that are
formed by the primary periplasmic oxidant DsbA[211]. Expression of ssDsbA-
PhoA-Bla in wild-type DHB4 cells conferred resistance to 100 mg/ml Amp as
evidenced by spot plating (Fig. 2.2a). When the same construct was expressed
in DHA cells, which lack DsbA, resistance to this concentration of Amp was no
longer observed. To quantify this difference in Amp resistance, single colonies
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of DHB4 and DHA were challenged on increasing levels of Amp and values for
the minimum bacteriocidal concentration (MBC) were determined. The MBC
for DHB4 cells expressing ssDsbA-PhoA-Bla was 33-fold higher than that mea-
sured for DHA cells expressing the same fusion (Table 2). Plating on LB agar
lacking Amp revealed no measurable growth difference between the DHB4 and
DHA cells (Fig. 2.2a), confirming that the difference in Amp resistance was due
to the DsbA-dependent oxidation of protein thiols required for PhoA folding.
To confirm that this difference was not attributable to redox-dependent changes
in the folding of the Bla moiety itself, cells expressing ssDsbA fused directly
to Bla were similarly plated on Amp. Consistent with earlier findings[77], the
periplasmic redox state had no measurable effect on the catalytic activity of Bla
as evidenced by the identical resistance phenotypes for DHB4 and DHA cells
expressing ssDsbA-Bla (Fig. 2.2a and Table 2). For comparison, we evaluated
cytoplasmic folding of PhoA in DHB4 cells using a previously developed assay
based on the twin-arginine translocation (Tat) protein export pathway[71]. In
this system, POI-Bla fusions are targeted by an N-terminal ssTorA signal pep-
tide to the Tat pathway, which requires that protein substrates fold correctly in
the cytoplasm prior to transport across the inner membrane[53]. Thus, the effi-
ciency of ssTorA-POI-Bla export, and the corresponding Amp resistance pheno-
type, is regulated by the folding behavior of the POI in the cytoplasm[73, 71]. As
expected, we observed that DHB4 cells expressing ssTorA-PhoA-Bla were sen-
sitive to 100 µg/mL Amp (Fig. 2.2a). This Amp sensitivity was due to the fact
that the cytoplasm of DHB4 cells is a reducing environment that renders PhoA
misfolded and incompetent for export transport via the Tat pathway. Western
blot analysis of the cytoplasmic and periplasmic fractions derived from DHB4
and DHA cells expressing the ssDsbA and ssTorA fusions confirmed that sol-
37
Figure 2.2: Redox-dependent folding reported via SRP selection. (a) An equiv-
alent number of DHB4 (dsbA+) and DHA (dsbA-) cells expressing either
ssDsbA-PhoA-Bla, ssTorA-PhoA-Bla, ssDsbA-Bla or ssDsbA-scFv13-Bla were
spot-plated on LB/agar containing either 50 µg/ml Cm (- Amp) or 100 µg/ml
Amp (+ Amp). (b) Western blot analysis of periplasmic (per) and cytoplasmic
(cyt) fractions derived from DHB4 (dsbA+) and DHA (dsbA-) cells express-
ing either ssDsbA-PhoA-Bla, ssTorA-PhoA-Bla or ssDsbA-scFv13-Bla. Samples
were blotted with Bla-specific antibodies.
uble expression of PhoA-Bla corresponded directly with the respective Amp
phenotypes (Fig. 2.2b). This analysis also revealed that ssDsbA-PhoA-Bla was
localized exclusively in the periplasm, consistent with a co-translational mode
of export. Proteolytic degradation of the fusion was observed in the periplasm
and to a lesser extent in the cytoplasm, but as discussed below, it does appear
to affect the assay readout for PhoA and does not occur for most of the other
proteins tested.
To determine whether the ability to report DsbA-dependent folding was a
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Table 2.1: Amp resistance conferred by different target proteins
Protein of interest Strain MBC (µg/ml) MIC (µg/ml)
alkaline phosphatase
PhoA DHB4 100 50
PhoA DHA 3 3
ssTorA-PhoA-Bla DHB4 6 6
ssTorA-PhoA-Bla DHA 12 6
Bla DHB4 3200 1600
Bla DHA 3200 1600
anti-β-gal scFv13
scFv13 (wild-type) DHB4 400 200
scFv13 (wild-type) DHA 50 50
scFv13-R4 DHB4 400 400
scFv13-R4 DHA 100 50
maltose-binding proteins
MalE (wild-type) DH5α 250 200
G32D DH5α 200 175
I33P DH5α 200 175
MalE31 DH5α 175 175
GroEL substrates
MetF DH5α 25 25
MetK DH5α 6 3
amyloid-β peptides
Aβ42 (wild-type) DH5α 12 12
A2 DH5α 25 25
A4 DH5α 25 25
B12 DH5α 25 25
B9 DH5α 25 25
H2 DH5α 50 25
GM6 DH5α 100 100
GM7 DH5α 100 50
GM11 DH5α 100 50
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general feature of our assay, we next analyzed the behavior of a single-chain an-
tibody fragment specific for β-galactosidase (scFv13)[155]. Like PhoA, scFv13
folding is dependent on the formation of two intradomain disulfide bonds,
one in the VH and one in the VL domain. In the absence of these bonds, the
scFv is only expressed at very low levels[155]. Similar to what was seen above,
DHB4 and DHA cells expressing ssDsbA-scFv13-Bla exhibited distinctly differ-
ent Amp resistance phenotypes (Fig. 2.2c). The MBC was 8-fold greater for
DHB4 cells compared to DHA cells expressing this construct (Table 2). Western
blot analysis revealed significant accumulation of soluble ssDsbA-scFv13-Bla in
the periplasmic fraction of DHB4 cells, while virtually no cross-reacting bands
were detected in any fraction (cytoplasmic or periplasmic) isolated from DHA
cells (Fig. 2.2d). This result confirmed that scFv13 folding and solubility was
dependent on disulfide bond formation. The fact that scFv13-Bla accumulated
predominantly in the periplasm provided additional support for our hypothe-
sis that proteins targeted to the SRP pathway are efficiently partitioned in the
periplasm. It is also noteworthy that, unlike the case of PhoA-Bla, we did not
observe any proteolytic degradation of the scFv13-Bla fusion. We also tested
scFv13-R4, a variant of scFv13 engineered previously to have greater solubil-
ity under reducing conditions[155]. In DHA cells, where the periplasm does
not support disulfide bond formation, scFv13-R4 showed a two-fold increase in
MBC over wild-type scFv13 (Table 2), consistent with the improved ability of
scFv13-R4 to fold correctly in the absence of disulfide bonds[155]. Interestingly,
expression of ssDsbA-scFv13-R4-Bla in DHB4 cells resulted in an 8-fold higher
MBC relative to expression in DHA cells. This is likely due to the fact that oxi-
dation of scFv13-R4 in the periplasm further increases the proteins stability by
the addition of at least one disulfide bond[155]. Like its parent, scFv13-R4 accu-
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Table 2.2: Amp resistance conferred by mammalian proteins
Protein 1 Domain2 Subcellular
location
ssDsbA
MBC
(µg/ml)3
ssTorA
MBC
(µg/ml)3
STE
ratio4
CASP2 (Hs) FL cytoplasm 50 50 0.00
CCND2 (Hs) FL cytoplasm 100 9 0.12
CD44 (Hs) FL extracellular 6 6 0.13
CDK4 (Hs) FL cytoplasm 50 12 0.25
CDKN1B (Hs) FL cytoplasm 400 50 0.10
Efna1 (Mm) EC extracellular 200 25 0.36
Efnb2 (Mm) EC1 extracellular 200 9 0.06
Efnb2 (Mm) EC2 extracellular 800 9 0.32
Epha2 (Mm) LB extracellular 6 6 0.03
Ephb2 (Mm) SAM cytoplasm 800 100 0.16
Ephb2 (Mm) TK cytoplasm 100 3 0.07
FOS (Hs) FL nuclear 100 25 0.01
GATA2 (Hs) FL nuclear 3 500 0.09
GFP (Av) FL cytoplasm 200 400 0.69
GRB2 (Hs) FL cytoplasm 800 30 0.31
HRAS (Hs) FL cytoplasm 3 25 0.52
JUN (Hs) FL nuclear 400 25 0.05
MAD (Hs) FL nuclear 6 25 0.52
Mdm2 (Mm) p53-bd nuclear 400 12 0.42
MMPI (Hs) FL extracellular 200 50 0.09
RAF1 (Hs) Ras-bd cytoplasm 200 400 0.52
mulated stably in cells with no apparent degradation (Fig. 2.2a).
Evidence for a universal assay of periplasmic protein folding.
We next tested whether changes in folding behavior unrelated to disulfide bond
formation could be discriminated using this selection strategy. Specifically, we
1Organism: Hs, Homo sapiens; Mm, Mus musculus; Av, Aequoria victoria
2Domain: FL, full-length; EC, extracellular; TK, tyrosine kinase; LB, ligand binding, SAM,
sterile alpha motif; bd, binding domain
3Approximately 500 CFUs were plated overnight at 37◦C
4Soluble versus total expression (STE) ratios were obtained for each protein by normalizing
the soluble expression data by the total expression data reported in Tables 2 and 3 of Dyson et
al. (2004). Values reported are the average over all 6x and 10x his-tagged constructs.
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tested several proteins that are physiologically expressed in the E. coli cytoplasm
(e.g., GST, MetF, MetK and TrxA) as well as GFP. We reasoned that some of these
would fold correctly in the periplasm. Indeed, selective plating of cells express-
ing these constructs revealed that GST, TrxA and GFP are each correctly folded
in the periplasm as evidenced by MBC values of 50, 100 and 200 µg/ml Amp,
respectively (Table 2). For comparison, expression of Bla fused to the maltose
binding protein (MBP), a native periplasmic protein that is known to be ex-
tremely soluble in E. coli[111], resulted in an MBC of 250 µg/ml Amp (Table 2).
Each of these was also was found to stably accumulate in cells with little to no
proteolytic degradation (Fig. 3a). We further reasoned that other proteins such
as MetF and MetK would misfold and/or aggregate outside of their native envi-
ronment. This is because MetF folding involves the binding of a flavin cofactor,
which would likely not be present in the periplasm[207]. Similarly, MetK has
redox-sensitive Cys residues that could become mis-oxidized in the periplasm.
In addition, both proteins are strictly dependent on the cytoplasmic chaperone
GroEL for correct folding[115]. As expected, the MetF and MetK fusions con-
ferred little to no resistance to cells plated on 100 µg/ml Amp (Fig. 3b) and re-
sulted in MBC values of only 25 and 6 µg/ml, respectively (Table 2). The weak
Amp resistance conferred by MetF and MetK corresponded with the complete
absence of each fusion protein following Western blot analysis (Fig. 2a), indi-
cating that incorrect folding of each protein in the periplasm was followed by
proteolytic degradation. To rule out the possibility that MetF and MetK are in-
capable of folding when fused to Bla, we expressed MetF-Bla and MetK-Bla that
lacked the ssDsbA export signals. Each of these folded very efficiently in the cy-
toplasm as evidenced by the relatively high Bla activity measured in the lysates
of cells expressing these constructs (Fig. 2b). For comparison, very little Bla
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activity was measured in the lysates of cells expressing ssDsbA-MetF-Bla and
ssDsbA-MetK-Bla. Thus, C-terminal fusions of Bla to MetF and MetK are indeed
capable of correct folding when expressed in the cytoplasm, but become mis-
folded and inactive when localized in the periplasm. The observation that GFP
folded correctly in the periplasm was surprising based on earlier findings that it
could not attain a fluorescent conformation when localized in the periplasm via
the Sec pathway[65, 72]. Indeed, cells expressing the ssDsbA-GFP-Bla fusion
were non-fluorescent (Fig. 2c). However, the absence of cell fluorescence could
not be attributed to global misfolding or aggregation of GFP in the periplasm
because ssDsbA-GFP-Bla conferred a strong Amp-resistant phenotype to cells
(Table 2 and Fig. 2c). For comparison, cells expressing GFP-Bla via the Tat
export pathway resulted in highly fluorescent cells that were similarly Amp-
resistant (Table 2 and Fig. 2c), consistent with earlier findings[71, 143]. From
these data, it is clear that GFP is soluble in both the cytoplasmic and periplas-
mic compartments; hence, the inability of GFP to fluoresce in the periplasm is
not attributable to its overall folding and stability in this compartment.
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Figure 2.3: A universal folding reporter. (a) Western blot analysis of whole
cell lystaes generated from an equivalent number of DH5α cells expressing
the ssDsbA-POI-Bla constructs as indicated. Samples were blotted with Bla-
specific antibodies. (b) An equivalent number of DH5α cells expressing ssDsbA-
MetF-Bla or ssDsbA-MetK-Bla were spot-plated on LB/agar containing either
50 µg/ml Cm (- Amp) or 100 µg/ml Amp (+ Amp). Nitrocefin hydrolysis ac-
tivity of whole-cell lysates from cells expressing MetF-Bla and MetK-Bla with
or without the ssDsbA signal peptide. Activity was measured as the initial ve-
locity of absorbance change at 486 nm. Relative Bla activity was obtained by
normalizing to the activity of the fusion without the signal peptide. Bla activity
was measured in triplicate and error bars represent standard error of the mean.
(c) DH5α cells expressing ssDsbA-GFP-Bla or ssTorA-GFP-Bla were spot-plated
as in (b). Fluorescence microscopy analysis (100X) of DH5α cells expressing
ssDsbA-GFP-Bla or ssTorA-GFP-Bla as indicated. (d) Western blot analysis of
periplasmic (per) and cytoplasmic (cyt) fractions generated from an equivalent
number of DH5α cells expressing ssDsbA-POI-FLAG fusions lacking the Bla
moiety for the clones indicated. Blots were probed by anti-FLAG antibodies.
GroEL was used as a fractionation marker by probing with anti-GroEL anti-
bodies (data not shown). GRB2 per and RAF1 per samples were included as
positive loading controls for the blot on the right. MBC values (µg/ml Amp)
corresponding to each protein are indicated below the panels
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To further test the limits of our selection strategy, we attempted to identify
mammalian proteins that fold correctly in the periplasm. For this, a total of
20 mammalian proteins and protein domains were evaluated for SRP-mediated
expression and selection. These proteins were of human or murine origin, and
represented several diverse protein families with extracellular, cytoplasmic and
nuclear cell locations (Table 2). We tested a collection of full-length and trun-
cated proteins, which are described elsewhere[56], by cloning each into the
pDMB selection vector as ssDsbA-POI-Bla fusions and determining the MBC for
each. For 15 of the proteins tested, the MBC was 50 µg/ml Amp (Table 2), sug-
gesting that these were all relatively well folded and soluble in the periplasm.
Of these, Efnb2(EC2), Ephb2(SAM) and GRB2 conferred a level of resistance
(800 µg/ml Amp) that was only 4-fold lower than the MBC measured for cells
expressing ssDsbA-Bla with no target protein, indicating that these were ex-
tremely soluble when expressed in the periplasm. The resistance conferred
by these 15 clones correlated with soluble expression of the fusion proteins,
as exemplified by the RAF1-Bla fusion (Fig. 2a). Only 5 of the clones (CD44,
Epha2(LB), GATA2, HRAS and MAD) exhibited MBCs of 6 µg/ml Amp that
were comparable to the MBC reported for plasmid-free wt MC4100 cells[142]
and indicative of poor folding and solubility. It is informative to compare the
MBC results obtained here for periplasmic folding versus the MBC values for
cytoplasmic solubility determined previously using a Tat-mediated folding re-
porter that also employed TEM-1 Bla[143]. For some of the target proteins (e.g.,
CCND2, Efnb2(EC1), Efnb2(EC2), GRB2 and Mdm2-p53-bd), strong resistance
was only conferred by periplasmic expression but not cytoplasmic expression,
whereas GATA2, HRAS and MAD conferred greater resistance following cyto-
plasmic expression compared to periplasmic expression (Table 2). We also ob-
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served that some of the proteins (e.g., EphB2(SAM), GFP, RAF1) were soluble in
both the periplasmic and cytoplasmic compartments while certain others (e.g.,
CD44, Epha2(LB)) were not very soluble in either of these subcellular locations
(Table 2).
To independently confirm soluble periplasmic expression, we expressed a
subset of the mammalian clones as ssDsbA-POI-FLAG chimeras in which the
C-terminal Bla moiety was replaced by a 9-residue FLAG epitope tag. Subcel-
lular fractionation analysis of several representative positive clones (i.e., those
conferring resistance to 50 µg/ml Amp) including GRB2, Mdm2(p53-bd), RAF1
and GFP revealed that each of these accumulated in the soluble periplasmic
fraction of wt cells (Fig. 2d). Conversely, we observed no soluble accumula-
tion in either the periplasmic or cytoplasmic fractions for two negative clones,
namely HRAS and MAD, that conferred resistance to 6 µg/ml Amp. These re-
sults confirm that soluble expression in the periplasm correlates well with the
resistance conferred by each of these clones.
cis- and trans-acting factors that affect protein folding in the periplasm.
We next determined whether the assay could report changes in folding robust-
ness caused by cis-acting factors such as sequence mutations or trans-acting fac-
tors such as molecular chaperones. For these studies, we employed E. coli MBP
and a collection of MBP variants that become kinetically trapped in off-pathway
intermediates that are prone to aggregation[3]. One of these, a double mutant
called MalE31 (G32D/I33P), reportedly forms inclusion bodies in the periplas-
mic space[18]. We cloned four different versions of MBP (wild-type (wt), G32D,
I33P, MalE31) into pDMB and evaluated their ability to confer Amp resistance
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to cells. Spot plating revealed that cells expressing wt MBP but not MalE31 were
resistant to 200 µg/ml Amp (Fig. 2.3a). Western blot analysis revealed that the
resistance phenotypes conferred by ssDsbA-MBP-Bla and ssDsbA-MalE31-Bla
correlated with the intracellular accumulation of each protein (Fig. 2b for MBP;
Fig. 2.3b for MalE31). Plating of the same cells on LB lacking Amp showed no
difference in growth phenotype for wt MBP versus MalE31 (Fig. 42.3a). The
measured MBC for the wt MBP fusion was 42% greater than its MalE31 coun-
terpart (Table2). It is noteworthy that while the MalE31 conferred significantly
less Amp resistance than MBP, these Bla fusions were not completely inactive.
This is in agreement with recent findings of Betton and coworkers who showed
that despite its poor folding efficiency in the periplasm, a fusion of MalE31-Bla
retained some catalytic activity[3]. Our previous findings showed that MalE31
expressed in the cytoplasm is somewhat soluble, albeit to a lesser extent than wt
MBP[71]. It has been shown that the periplasmic chaperone FkpA can decrease
aggregation of MalE31, while another periplasmic chaperone SurA did not af-
fect MalE31 aggregation[4]. In addition, a periplasmic chaperone called Skp is
well known for its ability to interact with a broad range of substrates[164] and
has been used to improve expression of phage-displayed proteins[22]. Based on
these data, we reasoned that a chaperone-mediated decrease in MalE31 aggre-
gation would lead to increased Bla activity in our assay. To test this, cells co-
expressing FkpA, SurA, or Skp with ssDsbA-MalE31-Bla were plated on Amp.
FkpA and Skp co-expression with ssDsbA-MalE31-Bla resulted in a measurable
increase in Amp resistance compared to the control case where ssDsbA-MalE31-
Bla was expressed alone (Fig. 2.3b). In contrast, SurA co-expression conferred
no measurable growth difference compared to the control (Fig. 2.3b). Cells
grown on control plates lacking Amp showed no differences in growth pheno-
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type (data not shown). Western blot analysis of periplasmic fractions confirmed
that co-expression of FkpA and Skp, but not SurA, increased the solubility of
ssDsbA-MalE31-Bla (Fig. 2.3c). Finally, to show that improved Amp resistance
resulted from an increase in MalE31 solubility and not by improved activity of
the Bla domain itself, we co-expressed each of the periplasmic chaperones with
ssDsbA-Bla and found that Bla activity did not increase in the presence of any of
the periplasmic chaperones (Fig.2.3d). In fact, co-expression of FkpA caused a
decrease in Bla activity as evidenced by lack of cell growth on 200 µg/ml Amp.
Interestingly, we found that co-expression of SurA increased the solubility of the
wt MBP fusion (Fig. 2.3b) suggesting that SurA promotes folding of wt MBP but
not MalE31.
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Figure 2.4: Effect of cis- and trans-acting factors on periplasmic protein folding.
(a) DH5α cells expressing wild-type (wt) MBP and its variants MalE31, I33P,
G32D as sandwich fusions between ssDsbA and Bla. An equivalent number of
cells were spot-plated on 100 µg/ml Amp (+ Amp) or 50 µg/ml Cm (- Amp).
Open triangle indicates increasing solubility of MBP. (b) An equivalent num-
ber of DH5α cells co-expressing periplasmic chaperones FkpA, Skp, and SurA
(or with empty pBAD18-Kan) along with wild-type (wt) MBP or MalE31 fusions
50
were spot plated at various dilution factors (as indicated to left) on LB/agar sup-
plemented with 200 µg/ml Amp and 50 µg/ml Kan. (c) Western blot analysis of
periplasmic fractions from cells co-expressing FkpA, Skp, and SurA chaperones
as indicated along with ssDsbA-MalE31-Bla. Samples were probed with Bla-
specific antibodies. Detection of DsbA using anti-DsbA serum was performed
as a loading control. (d) An equivalent number of cells co-expressing FkpA, Skp,
and SurA chaperones as indicated along with ssDsbA-Bla were spot-plated on
50 µg/ml Kan and either 800 µg/ml Amp (+ Amp) or 20 µg/ml Cm (- Amp).
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Enhancing the solubility of aggregation-prone proteins.
To demonstrate the utility of this system, we next attempted to isolate solubility-
enhanced protein variants in the periplasm using a directed evolution approach.
For this purpose, we inserted the 42-residue amyloid-β42 peptide (Aβ42) in
the POI position of our folding reporter. Aβ42 is the primary constituent in
dense amyloid fibrils that accumulate in the brains of patients with Alzheimers
disease[88]. As in humans, Aβ42 aggregates extensively when expressed in E.
coli[71, 253]. We and others have isolated variants of Aβ42 that were signif-
icantly more soluble in the bacterial cytoplasm compared to wt Aβ42[253, 71].
When expressed in the periplasm as a ssDsbA-Aβ42-Bla fusion, these solubility-
enhanced variants conferred increased Amp resistance to cells relative to wt
Aβ42 (Fig. 2.4a). The most soluble variant, clone GM6[253], displayed an 8-fold
higher MBC relative to wt Aβ42 (Table 2).
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Figure 2.5: Directed evolution of the Aβ42 peptide. (a) Spot plating of
an equivalent number of cells expressing fusions containing wild-type Aβ42
and solubility-enhanced variants GM11, GM7 and GM6 on 100 µg/ml Amp
(+ Amp) or 50 µg/ml Cm (- Amp). The variants are derivatives of Aβ42
with the following mutations: GM11 (H6Q/V12A/V24A/132M/V36G), GM7
(V12A/I32T/L34P) and GM6 (F19S/L34P). (b) Spot plating of an equivalent
number cells expressing evolved variants of Aβ42 with greater solubility than
wild-type Aβ42 at various dilution factors from overnight cultures. For com-
parison, wild-type Aβ42 and soluble variant GM6 are shown. (c) Amino acid
sequences of evolved Aβ42 peptides, along with Aβ42 and GM6 for compari-
son.
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Encouraged by the observation that growth selection could easily distin-
guish more soluble Aβ42 variants, we next attempted to isolate solubility-
enhanced Aβ42 variants from a combinatorial library of Aβ42 sequences. An
error-prone library of Aβ42 in pDMB was created that contained approximately
5x104 members. Plating of approximately 104 cells from this library on 25
µg/mL Amp resulted in 5 clones exhibiting an Amp-resistant phenotype above
wt). Each of these variants showed at least a 2-fold improvement in MBC over
wt Aβ42, with clone H2 exhibiting a 4-fold increase in MBC compared to wt (Ta-
ble 2). Interestingly, clone H2 contains the L34P mutation (Fig. 2.4c), which is
known to render Aβ42 less prone to aggregation[253]. The other isolated clones
had point mutations located primarily within hydrophobic stretches in the cen-
tral and C-terminal parts of Aβ42 that have been implicated by others as key de-
terminants in aggregation and fibril formation[253, 116]: A2 (M35T), B9 (V40D),
B12 (V37A) (Fig. 2.3c). It is noteworthy that this improvement in Aβ42 solubility
only required a single round of mutagenesis and selection, confirming the ro-
bustness of our assay for searching large volumes of sequence space for proteins
with altered structural characteristics.
Discussion
To date, several reporters of protein folding have been developed in E.
coli[102, 156, 240, 250, 34]. Such methods include: transcriptional fusion re-
porters that signal the cells genetic response to misfolding and aggregation of
the POI[130], and translational fusion reporters between the POI and a pep-
tide (e.g., tetracysteine motif binding site[102]), protein (e.g., chloramphenicol
acteyltransferase[156], GFP[240]) or split protein fragment (e.g., [250], GFP[34])
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whose activity is modulated by the folding behavior of the POI. Along similar
lines, we recently developed a protein solubility reporter that exploits the au-
thentic protein folding quality control mechanism of the E. coli Tat pathway[71].
Surprisingly, there are currently no reports of an analogous reporter system for
the periplasmic folding environment despite the significance of this compart-
ment for the expression and engineering of heterologous proteins[11, 219, 80].
This is due in part to the fact that GFP, one of the most useful cellular reporter
proteins that has been used to successfully assay cytoplasmic folding[240], fails
to reach a fluorescent conformation when routed to the periplasm via the Sec
export mechanism[65]. To remedy this, we developed a genetic reporter system
comprising a protein of interest fused between an N-terminal co-translational
export signal (ssDsbA) and a C-terminal selectable marker (Bla) that enables
intimate coupling between periplasmic protein folding and antibiotic resis-
tance. It should be noted that Bla gene fusions have been used previously
in E. coli to: (1) isolate genes encoding exported and membrane proteins of
prokaryotic[209] and eukaryotic[223] origin; (2) increase secretion efficiency of
exported and membrane proteins[27]; and (3) dissect membrane protein topol-
ogy and assembly[57]. However, no studies have used Bla for reporting the
folding robustness of target proteins in the periplasmic space. Another unique
aspect of our system is its use of the co-translational SRP pathway such that all
folding events are relegated exclusively to the domain of the periplasm. One
concern that arises when using Bla fusions is that proteolytic degradation can
release active Bla. Indeed, our experiments revealed some degradation of the
PhoA-Bla fusion. However, the degradation does not appear to have released
functional Bla because the MBC of these cells (100 µg/ml) was notably lower
than that seen for other cases where the ssDsbA-POI-Bla fusion was not prote-
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olyzed (e.g., MBP-Bla, scFv13-Bla, scFv13-R4-Bla, etc.). Even though we cannot
rule out the possibility in the future that certain protein fusions may be de-
graded to release functional Bla, we see no evidence in the cases that were tested
here. In fact, most of the other Bla fusions tested in this study experienced little
to no proteolytic degradation. Further, while the correctly folded ssDsbA-PhoA-
Bla fusion was not completely stable, the misfolded counterpart was even less
stable (i.e., completely degraded) as evidenced by the total absence of cross-
reacting bands on the Western blot. Thus, the assay was still able to reliably
report the folding robustness of the PhoA protein. It turns out that this was not
a unique phenomenon as many of the incorrectly folded proteins (e.g., MetF,
MetK) were efficiently degraded. In light of these results, we contend that any
Bla activity that might arise due to fusion instability should not impact the use-
fulness of the assay provided that proper negative controls are applied, as was
done here. Since in many cases protein expression in the periplasm is often
advantageous compared to expression in the cytoplasm[11, 219, 80], this assay
should be useful in the development and optimization of numerous biotech-
nological applications. For instance, we demonstrated that the assay is useful
for the isolation of solubility-enhanced variants from a combinatorial library of
protein sequences. These results indicate that this method could be used as a
platform for (1) engineering proteins with superior solubility, i.e. superfolder
proteins[178] and (2) pre-selection of large combinatorial libraries to eliminate
incorrectly folded proteins since soluble structure is a prerequisite for function.
In the future, it might be possible to use this system in combination with our
recently reported Tat-based cytoplasmic folding reporter[71], that also relies
on Bla activity, to comparatively and comprehensively explore the intracellu-
lar protein folding landscape. It might also be possible to use this selection in
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conjunction with fluorescence activated cell sorting (FACS) to isolate GFP vari-
ants that fold and function in the periplasm. In addition to sequence-related
determinants of protein folding, we have also shown that this assay can be used
to probe extrinsic factors (e.g., molecular chaperones) that contribute to pro-
tein solubility in the periplasm. The ability to characterize or discover factors
that affect folding in the periplasm and are orthogonal to protein sequence is
intriguing. A more comprehensive model of the periplasmic space could have
great implications for expression of proteins whose primary structure is con-
strained for reasons of, for example, therapeutic activity and immunogenicity.
Besides chaperones, this assay can also be used to analyze how periplasmic
post-translational modifications such as disulfide bond formation, as demon-
strated here, or even N-linked glycosylation[220] affect folding and solubility.
The stability conferred by disulfide bonds is often paramount to achieving sol-
uble expression of many therapeutic proteins in E. coli, many of which are cur-
rently produced in E. coli by inclusion body formation and re-folding proce-
dures due to disulfide-bond-related instability in the reducing cytoplasm. It
should be noted that for those proteins whose proper folding depends on post-
translational processing, the periplasmic folding reporter becomes a genetic re-
porter of that post-translational processing pathway. Finally, the fact that our as-
say can be used to evaluate the contribution of these processes to protein folding
should help illuminate the various ways in which disulfide bonds and glycosy-
lation reactions, or even their interplay[21], affects the structure, function and
stability of proteins.
Materials and Methods Strains and plasmids. DHB4 E. coli cells (F’ lacIq
pro/λ- ∆lacX74 galE galK thi rpsL phoR ∆phoA(PvuII) ∆malF3) or an isogenic
derivative of DHB4, namely DHA, that carries the dsbA::kan allele[53], were
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used for experiments where cellular redox state was investigated. All other
experiments were performed in DH5α or MC4100 E. coli cells as indicated.
Cloning was performed using standard molecular biological techniques and
protocols[197]. Plasmid pDMB was constructed by inserting DNA for the DsbA
signal peptide (ssDsbA; DNA nucleotides 1-57 of the E. coli dsbA gene) between
SacI and XbaI sites of pTrc99A-Cm[71]. Next, the gene encoding TEM-1 Bla was
inserted between the BamHI and HindIII sites. Finally, genes encoding differ-
ent POIs were inserted between the XbaI and SalI or BamHI sites resulting in
a sandwich fusion between ssDsbA and Bla. The resulting plasmids contained
very short linker sequences, Ser-Arg and Val-Asp-Gly-Ser, at the junctions of
ssDsbA-POI and POI-Bla (see Fig. 2.3a), corresponding to the translated por-
tions of the XbaI and SalI-BamHI sites, respectively. The POIs included: MetF,
MetK, GST, PhoA and TrxA, all of which were amplified from the E. coli genome
using colony PCR; maltose binding proteins MalE, MalE31, MalE-G32D and
MalE-I33P[18] and single-chain antibodies scFv13 and scFv13-R4[155], which
were kindly provided by J.-M. Betton; wild-type Aβ42 peptide and solubility-
enhanced Aβ42 variants GM7, GM11, and GM6[253], which were kindly pro-
vided by M.H. Hecht; and GFP, which was PCR-amplified from pTMB-GFP[71].
Plasmid pTMB is identical to pDMB except that it contains the signal peptide
of E. coli trimethylamine N-oxide reductase (ssTorA; DNA bases 1-126 of the
E. coli torA gene) between SacI and XbaI sites. Genes encoding the periplas-
mic chaperones SurA, FkpA, and Skp were PCR-amplified from E. coli genomic
DNA and inserted between the NcoI and SalI sites of pBAD18-Kan[87]. For
mammalian protein expression (and GFP), a vector called pDSALK was created.
This plasmid was created from a kanamycin-resistant version of pSALect[143]
and contains the DsbA signal sequence between the NotI and XbaI restriction
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sites. Mammalian proteins were cloned between the XbaI and either SalI or
BamHI sites of pDSALK, then transformed into MC4100 cells for plating on
Amp. For Western blot analysis of mammalian proteins expressed without the
Bla moiety, proteins or protein domains with N-terminal ssDsbA were PCR-
amplified from pDSALK constructs and cloned between the NcoI and HindIII
sites of pTrc99A. A FLAG affinity tag was added to the C-termini of each protein
or protein domain by PCR. Sequences of all plasmids constructed in this study
were confirmed by DNA sequencing. Expression of fusion proteins and cell
growth assays. Cells carrying a folding reporter plasmid were grown overnight
at 37◦C in LB medium containing 50 µg/mL chloramphenicol (Cm). Screening
of cells on LB agar was performed by first normalizing overnight cultures by
OD600 and then spotting 5 µL of serially-diluted (10-105-fold) cells on LB agar
plates containing 100 µg/mL Amp or 20 µg/mL Cm. LB agar plates used to
analyze co-expression of periplasmic chaperones were supplemented with 50
µg/mL kanamycin (Kan), along with either 20 µg/mL Cm or 200 µg/mL Amp
and either 0.2% arabinose or 0.2% glucose. The trc promoter allows for leaky
expression and therefore no IPTG was used to induce cultures. In all cases,
the plates were incubated for 16 h at 37◦C and then imaged using a Chemi-
Doc System (BioRad). For MBC/MIC determination, approximately 200 colony
forming units (CFUs) of each clone were plated on LB agar plates containing 0,
3, 6, 12, 25, 50, 100, 200, 400, 800, or 1600 µg/mL Amp or 20 µg/mL Cm. The
MBC was determined as the minimum Amp concentration at which no colonies
appeared on the plates. Minimum inhibitory concentration (MIC) was deter-
mined as the minimum concentration of Amp on which colony size or number
of colonies was significantly smaller than control. Protein analysis. Cells were
grown overnight at 37◦C in flasks containing 50 ml LB media with appropri-
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ate antibiotics. As above for the plating experiments, no IPTG was used to in-
duce cultures because the trc promoter allows for sufficient leaky expression.
Subcellular fractionation using the ice-cold osmotic shock procedure[53] was
performed on an equivalent number of cells to generate soluble cytoplasmic
and periplasmic fractions. Cytoplasmic fractions were obtained by sonication
of resuspended spheroplasts following release of periplasmic proteins. Western
blotting of these fractions was performed as previously described[53] using ei-
ther 10 µg/mL anti-β-lactamase, anti-FLAG M2 (Stratagene) at 1:500 dilution,
anti-alkaline phosphatase antibodies (Sigma) at 1:20,000 dilution, or anti-DsbA
serum diluted 1:5,000 (kindly provided by Dr. James Bardwell) as the primary
antibody and anti-mouse or anti-rabbit horseradish peroxidase conjugate di-
luted 1:2,500 (Promega, Madison, WI) as the secondary antibody. Bands were
visualized via chemiluminescent substrate (Bio-Rad) on Kodak film. The qual-
ity of all fractionations was determined by immunodetection of the cytoplas-
mic GroEL protein[53] or the periplasmic protein DsbA. Fractions from GFP-
expressing cells were assayed for fluorescence by loading 100-µL portions into
96-well plates and quantifying the GFP activity (ex: 488 nm; em: 509 nm) using
a microplate reader (Synergy HT, BioTek Instruments). Finally, soluble fractions
were assayed for Bla activity based on nitrocefin (50 µM) hydrolysis in 96-well
format as described[78]. All fluorescence and Bla activity measurements were
performed in triplicate. Fluorescence microscopy. Cells expressing ssDsbA-
GFP-Bla and ssTorA-GFP-Bla were visualized as described previously[121] us-
ing a Zeiss Axioskop 40 fluorescent microscope with Spotflex color digital cam-
era and filter sets for GFP (485 nm for excitation and 505 nm for emission) and
rhodamine (540 nm for excitation and 600 nm for emission). Library creation
and selection of clones. A library of Aβ42 sequences was created according to
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Fisher et al.[71], except that the plasmid backbone was pDMB. Briefly, error-
prone PCR was performed on the gene encoding the Aβ42 peptide. The gene
library was cloned between the XbaI and SalI sites of pDMB and estimated to
contain 50,000 members. Selection was performed by plating 2,000 CFUs per
plate on 25 µg/mL Amp. To eliminate false positives (e.g., small in-frame frag-
ments that confer higher-than-expected resistance to Amp), clones growing on
25 µg/mL Amp were inoculated in 96-well cultures and replica spot-plated as
above at 103 dilution on 25 and 100 µg/mL Amp. Only those clones that grew
on 25 µg/mL Amp but failed to grow on 100 µg/mL Amp were sequenced and
characterized by MBC determination.
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CHAPTER 3
AN IN VIVO ASSAY FOR BACTERIAL N-LINKED GLYCOSYLATION
Introduction
Protein glycosylation affects many protein properties including but not limited
to folding, solubility, pharmacokinetic activity, and receptor binding. Glycosy-
lation has been shown in many cases to enhance folding of glycoproteins [103].
In fact, it has been speculated that the addition of N-glycans has been an es-
sential factor that has allowed eukaryotes to express high amounts of complex
proteins that are well-folded [93]. Many proteins that are naturally glycosylated
will express poorly or not at all in the absence of glycosylation [251].
Glycosylation was long thought to be exclusive to eukaryotic organisms.
However, N-linked glycosylation was recently discovered in the pathogenic
bacterium Campylobacter jejuni [221]. Glycosylation has been found to be es-
sential for pathogenicity in this organism, but not overall cell viability [112]. In
2006, each gene in the 17-kb pgl (protein glycosylation) genetic locus was indi-
vidually characterized by Kelly and colleagues [114]. The locus consists of 13
genes, most of the products of which participate in glycosylation. The process
proceeds via five general steps: (1) saccharide and sugar-nucleotide biosynthe-
sis in the cytoplasm, (2) attachment of the base sugar (bacillosamine) to lipid
precursors on the membrane, (3) transfer of sugars to the glycan on the mem-
brane, (4) ”flipping” of the glycan from the cytoplasmic surface to the periplas-
mic surface of the inner membrane, and (5) transfer of the oligosaccharide to
the asparagine residue at the glycosylation site of the protein. The consen-
sus sequence for C. jejuni N-linked glycosylation has been determined to be
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D/E-X1-N-X2-S/T, where X1 and X2 are any amino acid except proline [129].
In addition, the structure of the heptasaccharide was revealed by NMR spec-
troscopy to be GalNAc-α1,4- GalNAc-α1,4-[Glcβ1,3]GalNAc-α1,4-GalNAc-α1,4-
GalNAc-α1,3-Bac-β1,N-Asn, where Bac is bacillosamine, 2,4-diacetamido-2,4,6-
trideoxyglucose. While the enzymes involved in this pathway have been rela-
tively well-characterized, the mechanism of involvement of N-linked glycosy-
lation in infection is not currently well-understood.
Not long after, the pgl locus of C. jejuni was successfully transferred into
E. coli, and it was shown that E. coli cells were capable of glycosylating pro-
teins using the glycosylation machinery of C. jejuni [239]. Since the transfer of
C. jejuni glycosylation to E. coli, several attempts have been made to engineer
the process. First, Schwarz et al., swapped the oligosaccharyltransferase (OST)
PglB from the C. jejuni system for a homologous protein from the related organ-
ismCampylobacter lari. TheC. lari OST was found to have relaxed substrate speci-
ficity for the consensus sequence compared to the C. jejuni OST. However, theC.
lari OST was not able to glycosylate a eukaryotic protein at its native consensus
site, N-X-S/T [202]. In another work, Schwarz et al. also showed that a mod-
ified pgl locus, lacking the bacillosamine biosynthesis and transferase genes
pglCDEF and glycosyltransferase pglI, synthesized a modified glycan that uti-
lizes N-acetylglucosamine in place of bacillosamine and lacks the branched glu-
cose motif. Proteins with this motif were then subjected to in vitro enzymatic
processing to produce protein bearing eukaryotic-like glycans [201].
The only high-throughput screening method currently available for analysis
of glycosylation is the recently reported glycophage display system, published
almost simultaneously by C¸elik et al.[36] and Du¨rr et al. [55]. Glycophage dis-
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play attaches a glycoprotein to the pIII protein of a bacteriophage, which can
then be panned for affinity to a glycan. The phagemid encoding the glycopro-
tein can then be recovered from bound phage particles. This technique shows
promise for engineering of glycosylation in E. coli, but suffers from limitations
due to its dependence on the affinity of a glycan-binding protein for the sugar
group of interest, incorporation of the glycoprotein fusion into the phage par-
ticle, and the efficiency of glycosylation in E. coli, which is currently relatively
low.
We recently developed a rapid protein folding assay for proteins in the
periplasm of E. coli [153]. Since protein glycosylation occurs in the periplasm,
we reasoned that adapting the protein folding assay for glycoproteins in E. coli
would allow us to (1) study the effect of glycosylation on folding of various C.
jejuni glycoproteins and (2) develop a genetic selection with the purpose of engi-
neering the glycosylation pathway using the versatile E. coli as a host. Here we
present the application of an assay for folding and solubility of glycoproteins
and its application to analysis of glycosylation in E. coli.
We hypothesized that since glycosylation can affect the folding and solubil-
ity properties of proteins, a reporter of periplasmic protein folding could re-
port changes in folding robustness effected by protein glycosylation. The as-
say is based on a tripartite fusion between: (1) an N-terminal signal peptide
from E. coli DsbA (ssDsbA), which has previously been shown to direct proteins
through the bacterial signal recognition particle (SRP)-dependent translocation
pathway[199], (2) the glycoprotein of interest, and (3) a C-terminal fusion of
mature TEM-1 β-lactamase (Bla). We have shown that the periplasmic folding
assay couples folding robustness to an ampicillin resistance phenotype.
65
In this study, we analyzed 18 different reported glycoproteins from C. je-
juni. In four cases we observed altered growth on ampicillin in the presence
of functional glycosylation machinery. Thus, simple selection on β-lactam an-
tibiotics such as ampicillin (Amp) enabled discrimination between glycosylated
and aglycosylated proteins. We also inserted glycosylation sites into a bacterial
protein the folding behavior of which has been has been shown to be affected
by glycosylation in vitro. We were able to recapitulate this result in an in vivo
assay.
Results
An in vivo assay for protein glycosylation
Peb3 is a glycoprotein adhesin from C. jejuni which has been hypothesized to be
involved with the transport of 3-phosphoglycerate from the extracytoplasmic
space [162]. It contains one glycosylation site at 118DSNIT122. As one of the first
N-linked glycoproteins to be discovered in C. jejuni, its crystal structure with
and without glycan has been solved [162]. In addition, a K135E mutation to
wild-type Peb3 has been found to allow for more efficient glycosylation. While
it was discovered that the overall structure of the protein did not differ signifi-
cantly with the addition of the glycan, it was found that the glycosylated K135E
variant possessed increased thermal stability of approximately 4.7◦C over the
aglycosylated protein.
Because this protein is well-characterized, we assayed its overall folding ro-
bustness using the previously reported folding assay. Briefly, we created a fu-
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sion of the gene encoding Peb3 to mature TEM-1 Bla and directed the polypep-
tide for co-translational transport using the N-terminal signal sequence of E. coli
DsbA. We then transformed this plasmid into CLM24 cells [67] containing either
pACYC-pglKan or pACYC-pglmutKan. These vectors express the entire pgl
operon on a plasmid, with the sole difference being the incorporation of two in-
activating point mutations into the pglB gene in the case of pACYCpglmutKan.
The cells were grown overnight and spot plated on varying levels of ampicillin
to characterize the Bla activity. Figure 3b shows the results of this assay.
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Figure 3.1: Glycosylation-dependent folding reported via SRP selection. (a)
An equivalent number of CLM24 cells expressing ssDsbA-Peb3-Bla (WT or
K135E)and either pACYC-pglKan (pgl+) or pACYC-pglmutKan (pgl-) were
spot-plated on LB/agar containing 200 µg/ml Amp and 50 µg/ml Kan. (b)
Western blot analysis of periplasmic fractions derived from CLM24 cells ex-
pressing the above constructs. Samples were blotted with Bla-specific antibod-
ies (anti-BLA) or hR6 serum, which is specific to the C. jejuni heptasaccharide.
(c) Nitrocefin hydrolysis activity of periplasmic fractions of above constructs.
Activity was measured as the initial velocity of absorbance change at 486 nm.
Specific Bla activity was obtained by normalizing to the total protein present in
the periplasmic fraction. Bla activity was measured in triplicate and error bars
represent standard error of the mean.
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In both wild-type and K135E variants, Peb3 shows an apparent increased
growth on ampicillin in the case of active glycosylation machinery. To confirm
that the growth increase was due to increased Bla activity, we performed a West-
ern blot analysis with an anti-Bla antibody (AbCam) (Figure 2.3b). Immunoblot-
ting with hR6 antiserum, which is specific to the C. jejuni glycan, confirmed
that Peb3 was glycosylated in both cases. Comparison of the bands in the hR6
(anti-heptasaccharide) blot also confirmed that glycosylation of K135E is more
efficient than wild-type, though perhaps not as dramatically as the reported dif-
ference when expressed in C. jejuni [162]. To confirm the increase in Bla activity,
we performed an in vitro Bla assay using the colorimetric substrate nitrocefin.
The glycosylated case showed an increase in BLA activity of 67% for the wild-
type and 20% for K135E. Thus, we were able to show that ampicillin resistance
was correlated with protein glycosylation.
Scanning the C. jejuni periplasmic glycoproteome
To determine if any other proteins behaved similarly vis-a`-vis glycosylation,
we tested an array of putative periplasmic glycoproteins from C. jejuni. The
proteins selected were confirmed to be glycosylated in an exhaustive glycopro-
teomic mass spectrometry study by Scott et al. [203]. In this study, which more
than doubled the number of known C. jejuni protein glycosyation sites, the
authors identified glycopeptides belonging to proteins localized on the inner
membrane, periplasm, and outer membrane/extracellular space. Of the pro-
teins identified, 28% are predicted to localize in the periplasm. We amplified 18
genes from C. jejuni genomic DNA and inserted them into the ssDsbA-POI-Bla
fusion to assess their folding robustness in E. coli in the presence and absence of
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Table 3.1: Single colony MIC and MBC measurements for C. jejuni proteins
tested in this assay.
Protein MIC/MBC in µg/mL Amp (pgl+) MIC/MBC in µg/mL Amp (pgl-)
Cj0114 25/25 25/25
Cj0143c 50/50 50/50
Cj0200c 400/400 400/400
Cj0168 200/400 400/400
Cj0515 12/25 12/12
Cj0610c 100/100 200/400
Cj0648c 800/800 800/800
Cj0694 50/50 50/50
Cj0843c 12/25 12/25
Cj1345 50/50 50/50
Cj1444 200/400 200/200
Cj1496 800/800 400/800
Cj1621 12/12 12/12
1670c 25/50 25/50
CjaA 400/400 100/200
HisJ 25/50 25/50
PEB3 WT 800/800 400/400
PEB3 K135E 400/800 400/400
glycosylation.
Of the proteins tested, most showed no significant change in ampicillin re-
sistance in the presence or absence of glycosylation (Table 3.1). One notable
exception was the CjaA protein. CjaA, also known a Cj0982, is a putative cys-
teine transporter, a major surface antigen and vaccine candidate. In C. jejuni,
CjaA is a lipoprotein that is located on both the inner membrane and cell sur-
face [167]. However, recent studies have shown that when expressed in E. coli,
CjaA primarily accumulates in the periplasm [254]. No crystal structure of the
glycosylated form is available, however the aglycosylated form has been crys-
tallized and its structure determined [167]. CjaA has one glycosylation site at
137DSNIS141.
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Figure 3.2: Glycosylation-dependent folding of CjaA and Cj0610c. (a) Spot plat-
ing as in Figure 3 on 200 µg/mL Amp and 50 µg/mL Kan (b) Western blot anal-
ysis as in Figure 3 (c) Nitrocefin hydrolysis activity as in Figure 3
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When the ssDsbA-CjaA-BLA was plated on ampicllin, we again observed a
positive correlation between glycosylation and ampicillin resistance ( Fig This
effect was confirmed by Western blotting with anti-Bla and hR6 serum). Ni-
trocefin assays confirmed that normalized Bla activity of periplasmic fractions
expressing CjaA-BLA was approximately 80% higher in the glycosylated case
(Figure 3.3).
Interestingly, not all proteins whose ampicillin-resistance phenotype was im-
pacted by glycosylation showed increased growth in the glycosylated case. Spot
plating of the fusion of protein Cj0610c-Bla actually results lower growth on
ampicillin in the presence of functional glycosylation machinery (FIgure 3.2).
Cj0610c is a putative periplasmic protein with homology to SGNH hydrolase
(as determined by sequence alignment by BLASTP, NCBI), a peptidoglycan o-
acyltransferase. Since this protein is poorly-characterized, it is not immediately
clear why glycosylation of this protein in a C. jejuni host would impact folding
robustness in a negative way.
Glycosylation affects folding of a bacterial immunity protein
in vitro studies of the bacterial immunity protein im7 have recently elucidated
several residues where introduction of a glycosylated Asn residue affected the
overall ∆G of folding. Glycosylation at position 27 was determined to increase
the overall stability of the protein by approximately 4 kJ/mol [41]. The con-
structs in question were created by protein ligation in vitro. To determine the
effects of glycosylation on this protein in vivo, we sought to introduce the im7
protein into our glycosylation assay. The protein does not natively contain the
glycosylation consensus sequence D/E-X1-N-X2-S/T, so engineered versions of
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the protein were created by site-directed mutagenesis. The two mutants created
encode either 25DQNAT29 or25ENNAT29, where N is residue 27. DQNAT was
chosen because of its efficiency of glycosylation in previous proteins [74], while
ENNAT was chosen to maintain the closest proximity to the original protein se-
quence in this area (25ENVAAT30, where V is WT residue 27). Figure 3.3b shows
the results of spot plating assays on the wild-type (aglycosylated), DQNAT and
ENNAT versions of the im7 protein. In both the DQNAT and ENNAT cases,
increased growth on ampicillin was observed in the cells with functional glyco-
sylation machinery. Western blotting confirmed that the appropriate constructs
were glycosylated. Some degradation of the constructs was observed, but this
is not uncommon in the case of fusion proteins [153]
Discussion
In this study, we observed four proteins whose growth on ampicillin was cou-
pled positively to protein glycosylation. This leads us to speculate on the fea-
sibility of developing a genetic selection for glycosylation in E. coli based on
growth on ampicillin. Further study and optimization of glycosylation condi-
tions may prove fruitful in this area.
We report that C. jejuni proteins Peb3 and CjaA showed increased folding
robustness when glycosylated. Many of the other C. jejuni proteins tested did
not show a significant difference in ampicillin-resistance phenotype due to gly-
cosylation (Table 3.1). To date, the impact of glycosylation on these proteins has
only been studied in a few cases. For example, glycosylation of Cj0143c was
found not to affect zinc transport or chick colonization [49]. Cj1496c function
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Figure 3.3: Glycosylation-dependent folding of im7 wild-type, DQNAT, and
ENNAT constructs (a) Spot plating as in Figure 3 on 400 µg/mL Amp and 50
µg/mL Kan (b) Western blot analysis as in 3 (c) Nitrocefin hydrolysis activity as
in 3
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was also not affected by glycosylation [108].
We suggest the following explanations for a lack of difference in behavior
between glycosylated and aglycosylated proteins: (1) Glycosylation in E. coli is
relatively inefficient. The highest reported efficiency of glycosylation of model
proteins in E. coli is roughly 40% of total extracted protein [176] and this was
acheived after significant optimization of the process by an intensive proteomic
study. Quantitatively measuring the efficiency of glycosylation is difficult, but
it is likely safe to say that glycosylation is relatively inefficent. (2) It is possible
that the glycan simply has no effect on overall protein folding. The contribution
of the heptasaccharide may be minimal depending on its location in the protein,
its ability to form hydrogen bonds, and the overall solubility of the protein. (3)
The kinetics of translocation, folding, and glycosylation may be different in the
reconsitituted system in E. coli than in the native environment of C. jejuni. There
are many examples in nature of glycans assisting in the protein folding pro-
cess [94], since the initial oligosaccharyltransferase step in eukaryotes occurs
co-translationally, though this phenomenon has not been thoroughly investi-
gated in C. jejuni. It is certainly possible that overexpression of the proteins of
interest on medium-high copy plasmids via cotranslational translocation (and
in a different organism with a different folding milieu) is not optimal for observ-
ing the full impact of glycosylation on a protein’s native folding pathway. (4)
Glycosylation has been shown to increase themal stability of proteins in many
cases [5]. It is generally thought that this occurs by destabilization of the un-
folded state of the protein, leading to an overall decrease in ∆G of folding. Cells
in this study were grown at 30◦C, but further study at a range of temperatures
may help elucidate changes brought about by glycosylation.
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On the other hand, the case of Cj0610c is interesting because it was found
that glycosylation impacted folding robustness negatively. Glycosylation has
been shown to negatively impact protein folding, specifically in the case of the
im7 protein [41]. Most of the glycosylated asparagines that were inserted into
im7 in the aforementioned study disrupted folding, while only one (at V27)
was observed to improve folding. This property of Cj0610c or other negatively-
impacted proteins could serve as the basis for high-throughput screens of in-
hibitors of glycosylation, which could lead to (1) greater understanding of the
overall glycosylation pathway and (2) potential drug targets against infection
by C. jejuni.
As the study of glycosylation in E. coli continues to evolve, it is clear that en-
gineering of the glycosylation machinery itself and/or the strains that produce
glycoproteins is necessary to make glycoprotein production in E. coli a viable
alternative to mammalian cell culture. Therefore, tools which allow for high-
throughput screening of the glycosylation status of a protein will undoubtedly
help to make this goal achievable.
Materials and Methods
Strains and Plasmids
Cloning was performed using standard molecular biological techniques and
protocols[197]. Genes from C. jejuni were amplified by PCR from genomic
DNA of Campylobacter jejuni subsp. jejuni NCTC 11168. The RNAseA-S32D
variant was amplified from pMIK81[128] (Markus Aebi). Variants of the im7
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protein were amplified from constructs provided by James Bardwell and mu-
tants were created by nested PCR. Plasmids used for this study were con-
structed using a modified version of vector pDMB, the construction of which
has been shown previously [153]. Briefly, plasmid pDMB was constructed by
inserting DNA for the DsbA signal peptide (ssDsbA; DNA nucleotides 1-57 of
the E. coli dsbA gene) between SacI and XbaI sites of pTrc99A-Cm[71]. Next,
the gene encoding mature TEM-1 Bla was inserted between the BamHI and
HindIII sites. The pDMB vector was modified to contain two SfiI restriction
sites flanking the protein of interest. This was accomplished by cloning the gene
encoding Cj0200c between XbaI and SalI sites in pDMB using the primers 5’-
aaaaTCTAGAGGCCGGCTCGGCCTTgatagtctaaaacttgaaggtactattgcac-3’ and 5’-
tttgtcgacAAGGCCttcagGGCCataagcttttttataacattgaatttcaatttttc-3’. Subsequent
cloning of all genes used in this study occured between the SfiI sites, except
for peb3 and variants, which were cloned between XbaI and SalI. The K135E
variant of Peb3 was generated by site-directed mutagenesis using overlap ex-
tension PCR. Genes from C. jejuni were amplified starting after the encoded sig-
nal sequence, as determined by SignalP 3.0 [60]. Plasmids pACYC-pglKan and
pACYC-pglmutKan were also kindly provided by Markus Aebi. Vector pDMB-
POI and either pACYC-pglKan or pACYC-pglmutKan were co-transformed
into strain CLM24 [67]. Sequences of all plasmids constructed in this study
were confirmed by DNA sequencing.
Expression of fusion proteins and cell growth assays.
Cells carrying a folding reporter plasmid were grown overnight at 37◦C in LB
medium containing 50 µg/mL chloramphenicol (Cm). Screening of cells on LB
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agar was performed by first normalizing overnight cultures by OD600 and then
spotting 5 µL of serially-diluted (10-105-fold) cells on LB agar plates containing
50 µg/mL kanamycin and either 20 µg/mL Cm or 0, 6, 12, 25, 50, 100, 200, 400,
800, or 1600 µg/mL ampcillin. In all cases, the plates were incubated 16 h at
30◦C and then imaged using a ChemiDoc System (BioRad). For MBC/MIC de-
termination, approximately 200 colony forming units (CFUs) of each clone were
plated on LB agar plates containing 0, 3, 6, 12, 25, 50, 100, 200, 400, 800, or 1600
µg/mL Amp or 20 µg/mL Cm. The minimum bacteriocidal concentration was
determined as the minimum Amp concentration at which no colonies appeared
on the plates. Minimum inhibitory concentration (MIC) was determined as the
minimum concentration of Amp on which colony size or number of colonies
was significantly smaller than control.
Protein analysis.
Overnight cultures of cells were inoculated into 10 mL LB with 40 µg/mL Cm
and 100 ug/mL Kan and grown at 37◦C to mid-log phase. They were then
induced with 0.1 mM IPTG and transferred to 30◦C for 6 hours. Subcellular
fractionation using the ice-cold osmotic shock procedure[53] was performed
on an equivalent number of cells to generate soluble periplasmic fractions.
Western blotting of these fractions was performed as previously described[53]
using either 10 µg/mL anti-β-lactamase (AbCam), or hR6 antiserum (pro-
vided by Markus Aebi) as the primary antibody and anti-mouse or anti-rabbit
horseradish peroxidase conjugate diluted 1:2,500 (Promega, Madison, WI) as
the secondary antibody. Bands were visualized via chemiluminescent substrate
(Bio-Rad) on Kodak film. Finally, soluble fractions were assayed for Bla activity
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based on nitrocefin (50 µM) hydrolysis in 96-well format as described[78]. All
Bla activity measurements were performed in triplicate.
80
CHAPTER 4
MODELING BACTERIAL N-LINKED GLYCOSYLATION USING AN
ADAPTED GENOME-SCALE MODEL OF ESCHERICHIA COLI
Protein glycosylation is an important post-translational modification that
has been shown to affect protein folding, solubility, pharmacokietic activity, and
other protein properties. Many therapeutic proteins are glycoproteins and the
glycosylation state of a protein has implications for its application downstream.
Recently, N-linked glycosylation, once thought to be exclusive to eukaryotes,
was discovered in a bacterium, Campylobacter jejuni. The subsequent functional
transfer of the gene locus responsible for glycosylation to the popular biotech-
nology host E. coli has opened up new opportunities for glycoprotein produc-
tion in this well-characterized, reliable workhorse organism.
In 2006, each gene in the 17-kb pgl (protein glycosylation) genetic locus was
individually characterized by Kelly and colleagues [114]. The locus consists of
13 genes, most of the products of which participate in glycosylation. The process
proceeds via five general steps (Figure 4.1) : (1) saccharide and sugar-nucleotide
biosynthesis in the cytoplasm, (2) attachment of the base sugar (bacillosamine)
to lipid precursors on the membrane, (3) transfer of sugars to the glycan on
the membrane, (4) ”flipping” of the glycan from the cytoplasmic surface to the
periplasmic surface of the inner membrane, and (5) transfer of the oligosaccha-
ride to the asparagine residue at the glycosylation site of the protein. The con-
sensus sequence for C. jejuni N-linked glycosylation has been determined to be
D/E-X1-N-X2-S/T, where X1 and X2 are any amino acid except proline [129].
In addition, the structure of the heptasaccharide was revealed by NMR spec-
troscopy to be GalNAc-α1,4- GalNAc-α1,4-[Glcβ1,3]GalNAc-α1,4-GalNAc-α1,4-
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GalNAc-α1,3-Bac-β1,N-Asn, where Bac is bacillosamine, 2,4-diacetamido-2,4,6-
trideoxyglucose.
Currently, production of glycoproteins in E. coli modified to carry the C. je-
juni glycosylation locus suffers from two major limitations. First, overall effi-
ciency of glycosylation is limited. The highest reported efficiency of glycosyla-
tion to date for a model protein is approximately 40 percent of total extracted
protein [176]. Second, the glycan attached to proteins is markely different from
eukaryotic glycans, being primarily a linear chain of N-acetylgalactosamine
(GalNAc) residues with one branched glucose as compared to a bi- or tri-
antennary branch comprising a tri-mannose core followed by GlcNAc, galac-
tose, and in humans, sialic acid. For glycoprotein production in E. coli to be
feasible and economically viable, these challenges must be met.
Only a few models of N-linked glycosylation have been published to date
[233, 131, 119]. Recently, a genome-scale model of Pichia pastoris was adapted to
account for protein glycosylation [43]. These models focus on glycosylation in
eukaryotic organisms and largely take advantage of the spatial organization of
enzymes present in the Golgi. Flipping of individual nucleotide-sugar precur-
sors into the Golgi, a major step in eukaryotic glycosylation, has also been con-
sidered. In E. coli, no such spatial organization exists and the glycan is flipped
into the periplasm en bloc [114].
Genome-scale models allow reserachers to study metabolic processes on the
scale of a complete organism[190]. For metabolic engineering applications,
modeling enables examination and simulation of metabolism as a whole, en-
abling the detection of pathways and reactions whose contributions to produc-
tion of a given end product may be non-intuitive [76, 2]. The most up-to-date
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genome-scale stoichiometric model of E. coli is iAF1260 [66], a model which
encompasses 1260 open reading frames. This model is unique not only in its
magnitude of reactions, but in the incorporation of a periplasmic space in the in
silico organism. Glycosylation occurs in E. coli in the periplasm, so the fact that
this model allows us to closely approximate the environment and reactions of
the periplasm is ideal.
In this study, we sought to to determine the metabolic effect of the introduc-
tion of glycosylation machinery into E. coli. We added the reactions correspond-
ing to the biosynthesis, flipping, and transfer of glycan to a target protein to the
iAF1260 model. Using flux balance analysis, we measured the effect of simu-
lated gene knockdown and simulated gene overexpression on the production
of glycosylated protein. With this information, we assayed several knockout
strains of E. coli for production of glycan and compared the results to our find-
ings
Results and Discussion
Adaptation of a genome-scale model of E. coli for N-linked glycosylation of
proteins
We simulated knockdown of individual genes in E. coli by constraining the cor-
responding fluxes to zero in the model and maximizing production of glycopro-
tein. To select for conditions that did not impair cell growth, during these sim-
ulations biomass was constrained to be 90% of the maximum possible biomass
production under the simulation conditions. We performed this experiment
under uptake conditions similar to growth in LB media. This simulated LB
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Table 4.1: Reactions that lead to knockdown of protein glycosylation when
knocked out.
Reaction Class % Knockdown
of protein
glycosylation
Undecaprenol pyrophosphate
regeneration
LPS synthesis 100
Undecaprenol transfer to cyto-
plasmic inner membrane
LPS synthesis 100
UDP-glucose synthesis Glycan biosynthesis 100
Glucose-6-phosphate to
glucose-1-phosphate isomeriza-
tion
Gluconeogenesis 100
Ribulose-5-phosphate to Ribose-
5-phosphate isomerization
Pentose Phosphate Pathway 96
Glutamate amination to glu-
tamine
Amino Acid Biosynthesis 79
CO2 export Exchange 68
1,3-bisphosphoglycerate to
glyceraldehyde-3-phosphate
Gluconeogenesis 50
3-phosphoglycerate to 1,3-
bisphosphoglycerate
Gluconeogenesis 50
Fumarate hydrolysis to malate TCA Cycle 7
Succinate oxidation to fumarate TCA Cycle 6
media contained all 20 amino acids plus the requisite minimal media salts. Ta-
ble 4 shows the top results of the knockout experiment, with the exception of
the reactions corresponding to the C. jejuni pgl locus, all of which lead to total
knockdown of glycosylation.
While some reactions make intuitive sense, e.g., recovery of the phosphory-
lated lipid carrier into the cytoplasm and ribose phosphate synthesis for creation
of nucleotide-sugar donors, some are less obvious. For example, the involve-
ment of the TCA cycle is interesting. We hypothesize that the products of the
TCA cycle are contributing to gluconeogenesis via pyruvate carboxylation and
synthesis of sugars.
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Flux Coupling Analysis
To systematically determine which reactions were coupled to protein glycosy-
lation, we implemented the Flux Coupling Finder (FCF) algorithm [31] on the
modified genome-scale model. Briefly, this algorithm finds coupled fluxes by
first constraining a target reaction to a maximum and individually minimizing
each reaction, then constraining each reaction to the determined maximum and
minimizing the target reaction.
When using protein glycosylation with the C. jejuni glycan as the target re-
action, we found that 195 reactions were directionally coupled to the target flux.
Among these reactions were many of the reactions found in the TCA cycle and
gluconeogenesis (Figure 4.2). Interestingly, the flux coupling finder isolated
isocitrate lyase as coupled to glycosylation. This reaction diverts flux from the
TCA cycle to the glyoxylate shunt. In doing so, it bypasses the decarboxyla-
tion of α-ketoglutarate, conserving carbon. This allows for more carbon-efficient
generation of malate and oxaloacetate, which can be used for sugar biosynthesis
via gluconeogenesis.
In a recent, large-scale proteomic study of protein glycosylation in E. coli,
isocitrate lyase was found to be upregulated in cells producing glycoprotein
[176]. Overexpression of this gene resulted in a 3-fold increase in glycosylation
efficiency. We also found that the glyoxylate shunt was important in glycosy-
lation and that the glyoxylate cycle and gluconeogenesis are coupled to glycan
synthesis when cells are grown on simulated LB medium. The reason for the
inclusion of this pathway is likely that gluconeogenesis is required for sugar
biosynthesis since it has been demonstrated that cells grown on LB use amino
acids as a carbon source [206] and very little fermentable sugar is available for
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Figure 4.2: Reactions of the central carbon metabolism that are coupled to pro-
tein glycosylation. Arrows in bold indicate coupled reactions.
87
cell growth.
Reverse Knockdown Studies
We next sought to determine which reactions (if any) led to increased glycosy-
lation when knocked down. Such reactions would likely be sources of diverted
flux from the glycosylation pathway. The nature of the flux balance analysis
algorithm makes this question difficult to answer since maximization of glycan
will automatically zero out unconstrained competing reactions. Therefore, we
solved the model for the maximum flux of each reaction with the constraint that
the minimum biomass generation be 90% of the maximum biomass produc-
tion given the uptake constraints (simulated LB). Next, each reaction was con-
strained to the maximum flux and glycosylation was maximized. This condi-
tion simulates overexpression of the gene corresponding to a particular reaction
flux. Some of the reactions that decreased glycosylation when ”overexpressed”
are noted in Table 4.
Interestingly, many of the reactions that knock down glycosylation when
overexpressed are the backward reactions of those found to decrease glyco-
sylation when knocked out. For example, the interconversion of fumarate to
succinate is obviously important, which underscores the overall importance of
regulation of the TCA cycle in glycan biosynthesis and subsequent protein gly-
cosylation.
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Table 4.2: Reactions that lead to knockdown of protein glycosylation when over-
expressed.
reaction class % knockdown
of protein
glycosylation
Citrate isomerization to cis-
acotinate
TCA cycle 100
Ribulose-5-phosphate iso-
merization to arabinose-5-
phosphate
Pentose Phosphate Pathway 100
Fumarate reduction to succinate TCA cycle 75
Glyoxylate reduction to glyco-
late
Glyoxylate Metabolism 75
Leucine synthesis from 4-
monoisopentanone
Amino Acid Metabolim 70
Attachment of GlcNAc to unde-
caprenol
LPS synthesis pathway 67
N-acetylglucosamine-6-
phosphate deacetylation
Sugar biosynthesis 61
Succinyl-CoA synthesis TCA cycle 43
Citrate synthase TCA cycle 30
Experimental Verification of Knockout Studies
To determine whether our determined knockouts affected protein glycosylation
in real cells, we performed an assay for glycan production. It is known that
there exists crosstalk between the LPS synthesis pathway and the glycosylation
pathway in E. coli [67]. after glycan is flipped to the periplasmic side of the inner
membrane, that some is transferred to the lipid carrier, lipid A, and exported to
the surface of the cell. We reasoned that production of the glycan on the cell
surface would be a reasonable measure of total glycan production, which in
turn would reasonably approximate protein glycosylation.
We selected four gene knockouts from the Keio strain collection, which con-
tains single, in-frame knockouts of almost every identified gene in E. coli [7]
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and transformed them with the pACYC-pgl plasmid containing the glycosyla-
tion locus from C. jejuni. Many of the reactions we identified as either positively
or negatively affecting glycosylation are either essential for cell growth or are
catalyzed by multiple isozymes, making single-knockout study difficult. The
knockouts selected were (1) acnB (acotinase B) which catalyzes citrate isomer-
ization as part of the TCA cycle, (2) gltA (citrate synthase), which synthesizes
citrate from oxaloacetate, (3) pck (pyruvate carboxykinase), which is a the first
step in gluconeogenesis, and (4) rpiA, which isomerizes ribulose-5-phosphate to
ribose-5-phoshate for inclusion into the pentose phosphate pathway. We then
grew cells to mid-log phase to approximate the steady state that is simulated in
the flux balance analysis model.
Cells at mid-log phase were spun down and resuspended in AlexaFluor-
conjugated soybean agglutinin (SBA). SBA binds terminal galactose and N-
acetylgalactosamine residues, so glycans on the cell surface will be fluorescently
labeled for analysis by flow cytometry. We also selected this method because it
is easily adaptable to high throughput studies.
The results of this experiment can be found in Figure 4.3. We expected that
knockout of acotinase B and citrate synthase would increase glycosylation by
decreasing flux away from oxaloacetate. Uexpectedly, we found that the knock-
outs produced the opposite effect, decreasing fluorescence by roughly 2.5- and
5-fold, respectively. Knockouts of pyruvate carboxykinase and ribulose phos-
phate isomerase were expected to decrease glycosylation by decreasing gluco-
neogenesis and flux to the pentose phosphate pathway respectively [39]. In
these cases, fluorescence did decrease roughly 5- and 4.5-fold. This result con-
firmed that our model was able to predict the behavior of some knockouts but
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Figure 4.3: Reactions of the central carbon metabolism that are coupled to pro-
tein glycosylation. Arrows in bold indicate coupled reactions.
not others.
A key weakness of flux balance analysis is the absence of parameters for
metabolic regulation. Often cells with a gene knocked out can compensate
by upregulating production of other pathways. The application of regulation
would certainly improve the chances of predicting cell behavior during glyco-
protein production. Also, the steady-state nature of flux balance analysis does
not take into account kinetic parameters, which could be found to be important
in the glycosylation process.
We have adapted a genome-scale model of E. coli to account for N-linked gly-
cosylation using the C. jejuni glycosylation pathway. The TCA cycle, glyoxylate
cycle, and gluconeogenesis were found to be important in growth and protein
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glycosylation in the simulated E. coli. Two gene knockouts that we predicted
to decrease glycosylation did accomplish this in cells. However, two knockouts
that we predicted to increase glycosylation did not result in increased glycosyla-
tion compared to wild type. Further study of this network is needed to elucidate
factors that can increase the efficiency of glycosylation.
Materials and Methods
Flux Balance Analysis Modeling
The reactions of the iAF1260 model were imported via the Systems Biology
Markup Language (SBML). Reactions added were constructed in SBML and
added to the iAF1260 model. The SBML was then used to generate a stoichio-
metric matrix with the UNIVERSAL code generation software. Reactions added
consisted of sugar biosynthesis, flipping, and transfer of the glycan to a protein
of interest. The adapted model accounted for 3600 reactions, 1290 genes, and
1972 species segregated into 3 compartments: cytoplasm, periplasm, and extra-
cellular space. For a list of the reactions added to the model, see Table
The model was optimally solved by linear programming using the glpk
solver in OCTAVE. In cases where the maximization of biomass was not the
objective function, the model was constrained to produce biomass at 90% of the
maximum rate given the growth conditions.
Because enzymes are largely implicit in the flux balance analysis model, a
protein species named ”targetprotein” was created to act as an acceptor for
the glycan. Production of this protein was not factored into the biomass ob-
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Table 4.3: Reactions added to the E. coli iAF1260 model to study the metabolic
effects of glyocosylation
Enzyme Reaction Reference
Gne UDP-GlcNAc/UDP-GalNAc
epimerase
[16]
PglF UDP-GlcNAc dehydratase (Bac
synthesis)
[200]
PglE UDP-2-acetamido-2,6-dideoxy-
αa-d-xylo-4-hexulose amino-
transferase (Bac synthesis)
[200]
PglD N-acetyltransferase (Bac synthe-
sis)
[175]
PglC Bacillosamine transferase to un-
decaprenol
[83]
PglA GalNAc transferase to
undecaprenol-Bac
[247]
PglH GalNAc transferase (3 reactions) [229]
PglJ GalNAc transferase [82]
PglI Glc transferase [114]
PglK Flippase (ATP-driven) [114]
PglB Promiscuous oligosyltrans-
ferase
[145]
WaaL1 Transfer of glycan to Lipid A [67]
wzx 1 Promiscuous flippase (Non-
ATP-driven)
[1]
jective function. Glucose/minimal media conditions were analyzed as in [66].
Simulated LB media was defined as the minimal media salts from the glu-
cose/minimal media conditions, plus the 20 amino acids as a carbon source.
Knockout and Overexpression Studies
For knockout studies, we first solved the model with no constraints and an obec-
tive funciton of maximization of biomass. We then constrained for the produc-
tion of biomass and set the objective function to maximization of glycan flipping
into the periplasm while constrained each individual reaction flux to zero, one
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at a time, simulating knockdown of the gene responsible for this reaction. Reac-
tions that reduced glycan production significantly were noted.
For overexpression studies, we first solved the model with no constraints
and an objective funciton of maximization of biomass. Next, we first solved the
model with no constraints and an objective funciton of maximization of each in-
dividual reaction. We then constrained for the production of biomass and set the
objective function to maximize each individual flux. With this information, we
solved the model again, this time constraining for both 90% biomass production
and maximum flux at each reaction. The objective function was the maximum
glycosylation of protein with the C. jejuni glycan. Reactions that decreased gly-
cyosylation when significantly ”overexpressed” were noted. The flux coupling
finder (FCF) algorithm of Burgard et al. [31] was employed to determine reac-
tions coupled to the production of glycosylated protein.
Analysis of glycan production
Knockout strains from the Keio strain collection [7] were transformed with the
pACYC184-pgl plasmid (kindly provided by Markus Aebi) and grown into
mid-log phase on LB media supplemented with 0.50% glycerol µg/mL chlo-
ramphenicol. Glycan production was measured by fluorescent labeling of gly-
can on the cell surface by staining with fluorescent soybean agglutinin (SBA)-
AlexaFluor 488 nm conjugate (Invitrogen). Cells were resuspended in 50 µg/mL
SBA-AlexaFluor in PBS, incubated for 1 hour, then washed with 0.5 mL PBS be-
fore analysis on a BD FACScalibur flow cytometer.
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CHAPTER 5
AN ASSAY FOR REPORTING PROTEIN-PROTEIN INTERACTIONS IN
THE BACTERIAL PERIPLASM
Introduction
Protein-protein interactions abound in living cells and understanding in vivo
protein interactions is key to understanding many cellular functions. Several
tools currently exist to detect protein-protein interactions. The most widely
used is the yeast two-hybrid assay, developed in 1989 [69]. Briefly, this as-
say comprises two proteins fused to a split yeast transcription factor (originally
GAL4) which binds a promoter upstream of a reporter protein. If the proteins
interact, the activity of the transcription factor is reconsitituted and transcription
of the reporter protein is upregulated, providing a signal. The yeast two-hybrid
assay is highly versatile and is still widely used for analysis of the complex
interactions of eukaryotic cellular networks. However, it has its drawbacks,
including its location in the nuclear environment of the eukaryotic yeast host,
which may differ from the in vivo interaction environment of the proteins of
interest.
In recent years, an alternative to the yeast two-hybrid assay has arisen in
the form of the protein complementation assay. This method fuses the proteins
of interest to a split reporter protein such as GFP [34, 32], YFP [25], luciferase
[120] , dihydrofolate reductase [191] , or β-lactamase [78, 249]. The laboratory
of Stephen Michnick (Biochemistry, University of Montreal) has developed, us-
ing protein engineering techniques, many split proteins whose individual frag-
ments are inactive. Upon interaction of the proteins of interest the split reporter
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protein regains its activity. Figure 5.1 shows a schematic of the PCA. In 2002,
both the Michnick lab [78] and the laboratory of Helen Blau (Stanford) [249]
published versions of a split β-lactamase protein complementation assay, both
intent on monitoring protein-protein interactions in mammalian cells using Bla.
Both constructs were produced in E. coli. The Michnick lab construct, contain-
ing no signal sequence, measured Bla activity in vitro by nitrocefin colorimetric
assay. The Blau lab incorporated Sec signal peptides into both fragments and
plated cells on ampicllin. This was the first instance of in vivo protein comple-
mentation measured in the periplasm of E. coli. Both groups then went on to
study protein interactions in mammalian cells using signal-less Bla.
The periplasm has reduced molecular crowding, high sensitivity to extracel-
lular conditions which allows simple modification of the local environment, and
an oxidizing milieu that permits disulfide bond formation. In addition, post-
translational modifications that are important for producing human-like thera-
peutic proteins, such as glycosylation, have been demonstrated in the periplasm
[239] . Finally, full-length human immunoglobulins (IgGs), which require disul-
fide bond formation for functional expression, have been successfully expressed
in the periplasm of E. coli [157]. Cytoplasmic expression of antibody fragments
is unfavorable, often requiring several rounds of directed protein evolution to
eliminate the need for disulfide bonding. Even in these cases, single-chain vari-
able fragment (scFv) expression and activity is far below that of scFvs expressed
in the periplasm.
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Figure 5.1: (a) Schematic of the plasmids used in this work. The reporter is a
two-plasmid system in which genes of interest are fused to the inactive frag-
ments of BLA. Fos and Jun are used here as examples, and proteins of interest
would replace Fos and Jun in their respective constructs. (b) Schematic of the
protein complementation assay. Protein interactions result in formation of an ac-
tive BLA complex which is able to hydrolyze ampicilin, conferring an antibiotic-
resistance phenotype.
Results and Discussion
We hypothesized that detecting protein interactions in the periplasm can be
used to engineer antibody fragments with in vivo activity in the periplasm.
The periplasm is ideal for antibody engineering as its oxidizing environment
allows for the formation of disulfide bonds, which many antibody fragments
require to function [6]. Our approach was to fuse known interacting protein
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domains to genes encoding 2 split β-lactamase fragments using a two-plasmid
system, the templates for which were kindly given by Helen Blau [249] (see Fig-
ure 5.1a). The α fragment encodes residues 1-196 of TEM-1 Bla, while the ω
fragment encodes residues 198-286 out of 286. The α fragment contains the na-
tive signal sequence of Bla (residues 1-23), which targets the C-terminally fused
protein to the Sec translocon for transport into the periplasm. In our construct,
the protein of interest fused to the ω fragment is targeted to the SRP pathway
for co-translational translocation.
Antibody-Antigen Interactions are reported in 2 cases
To determine the ability of our assay to detect and eventually engineer
antibody-antigen interactions, we cloned interacting protein pairs as well as
non-interacting proteins into two plasmids carrying the two inactive BLA frag-
ments (Figure 5.1a). In this study we examined two antibody-antigen pairs.
First, we tested an scFv which is known to bind the GCN4 leucine zipper. In
addition to the scFv and wild-type GCN4 pair, we also tested a double proline
mutant, GCN4-PP as an antigen for the scFv. GCN4 is normally a homodimer,
but a double proline mutant of GCN4 (GCN4-pp) exhibits reduced dimeriza-
tion, thereby reducing the amount of inactive α/α dimers in our assay. Figure
5.2 shows the results of spot plating of the interacting pairs, with α-Jun as a
negative control. The spot plates correspond to a 16-fold higher MBC (min-
imum bacteriocidal concentration, see Materials and Methods for full defini-
tion of MIC/MBC) on ampicillin for GCN4-PP and a 2-fold higher MBC for the
GCN4 wild-type (homodimer). A difference of this magnitude is promising for
future library selection processes.
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In the case of GCN4, we had already tested an antibody fragment that bound
a leucine zipper, a short peptide fragment. Since a goal of this assay is engineer-
ing protein-protein interactions, we wanted to examine an antibody fragment
with a protein antigen. We chose D10, an scFv with affinitiy for the phage pro-
tein gpD, an 11.4 kDa capsid protein from bacteriophage lambda [124]. Indeed,
our results with D10 were similar (spot plating shown in Figure 5.2), with an
MBC roughly 8-fold higher than the Jun negative control and 16-fold higher
than the GCN4-PP negative control.
Leucine zipper interactions are reported reliably
The hydrophobic interaction between Fos and Jun leucine zippers is well-
documented and these proteins are often used as standards for protein
interaction[249]. The KD of their interaction has been reported in the nanomolar
range [183]. In our study, we fused Fos to the ω fragment and Jun to the α frag-
ment. As a negative control, we incorporated as a potential binding partner the
leucine zipper GCN4, which does not bind Fos. When placed in the PCA, Fos
and Jun were found to have ampicillin activity well above that of the negative
control Figure 5.2b. After successful spot plating, we further characterized the
interactions by constructing a series of point mutants which have been shown
to have lower affinity (due to knockout of leucine residues). The MIC/MBC of
these interactions and spot plating of these mutants can be found in Figure 5.3.
It is notable that our assay is apparently able to correlate Bla activity with levels
of interaction along a spectrum of affinities. Further study of the expression and
actual affinities of these variants is warranted To verify that the intermediate Bla
activity is indeed due to intermediate affinities and not changes in solubility of
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Figure 5.2: Protein complementation of interacting domains. (a) Spot plating
of Fos and Jun leucine zippers on 50 µg/ml Amp. GCN4, another leucine zipper,
but one that does not interact with Fos, is used as a negative control. (b) Spot
plating as in (a) of antibody fragment scFv-GCN4 and its antigen, the GCN4
leucine zipper. GCN4-PP is a double point mutant to wild-type GCN4 which
reduces homodimerization of the leucine zippers. Jun is used as a negative
control. (c) Spot plating as in (a) of scFv D10[124], with affinity to phage protein
Gpd. Jun and GCN4 used as negative controls.
the point mutants.
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Figure 5.3: Interaction of Fos and Jun variants (a) Spot plating as in Figure 5.2
of Fos/Jun variants. Note: notations such as L3V refer replacement of leucine
3 with valine, not necessarily residue 3. Similar growth for all variants was
confirmed on Cm/Kan plates (data not shown) (b) MIC (blue) and MBC (red)
measurements of Fos and Jun variants pictured in (a).
Continued development of this assay is warranted to optimize plating Amp
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concentration, number of cells, etc. for the inclusion of selections for engi-
neered protein interactions. The considerable difference in MIC/MBC between
the GCN4 and Jun cases with scFv(GCN4) implies that selection of interactions
from a randomized or even naı¨ve group of proteins is not far away.
Materials and Methods
Construction of vectors
All cloning was performed using standard molecular biological techniques.
A gene sequence comprising a (GGGGS)3-NGR linker sequence followed by
residues 198-286 of TEM-1 BLA was cloned between the BamHI and HindIII
sites of pDMB (Mansell et al., manuscript in preparation) to create pDMB-
ωBLA. Genes to be fused to the ωBLA fragment were then cloned into this vec-
tor between XbaI and SalI sites. Genes to be fused to the αBLA fragment were
cloned between the KpnI and BamHI sites of vector αGS-Jun [249]. Fos and Jun
leucine knockouts and scFv-GCN4 were as in [245]. Template DNA for scFvs
D10, and gpd was kindly provided by Andreas Plu¨ckthun.
Plasmid pMAZ360 was kindly provided by George Georgiou. To create pα-
IgG(GCN4), we first digested pMAZ360-YMF10 with DraI to remove the bla
gene from this vector. Chloramphenicol acetyltransferase (cat) was ligated in its
place by blunt-end ligation to create pMAZcat. Next, we designed DNA (syn-
thesized by Genscript) that would replace the variable regions VL and VH of
the YMF10 IgG with αBLA-VL(GCN4) and VH(GCN4). We ligated this DNA
fragment into pMAZcat with XbaI and HindIII to create pα-IgG(GCN4). Plas-
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mid pω-GCN4-PP was created by ligation of the GCN4-ωBLA fragment from
pDMB-ωBLA between the SphI and ClaI sites in pLYNK-YFP1, a spectinomycin-
resistant vector described elsewhere [126].
Expression of fusion proteins and cell growth assays
E. coli MC4100 cells were co-transformed with plasmids pDMB-P1-ωBLA (CmR)
and aGS-P2 (KanR), where P1 and P2 represent proteins of interest. Cells were
grown overnight at 37C in LB medium containing 20 µg/mL chloramphenicol
(Cm) and 50 µg/mL kanamycin (Kan) or 50 µg/mL spectinomycin. Screening
of cells on LB agar was performed by first normalizing overnight cultures by
OD600 and then spotting 5 µL of serially diluted (10-10-fold) cells on LB agar
plates with 12, 25, 50, or 50 µg/mL of ampicillin (Amp). In all cases, the plates
were incubated 16 h at 37C and then imaged using a ChemiDoc System (Bio-
Rad). For MBC/MIC determination, approximately 200 colony forming units
(CFUs) of each clone were plated on LB agar plates containing 0, 3, 6, 12, 25, 50,
100, 200, 400, 800, or 1600 µg/mL Amp or 20 µg/mL Cm. The minimum bacte-
riocidal concentration was determined as the minimum Amp concentration at
which no colonies appeared on the plates. Minimum inhibitory concentration
(MIC) was determined as the minimum concentration of Amp on which colony
size was significantly smaller than control.
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CHAPTER 6
CONCLUSIONS AND FUTURE DIRECTIONS
Abstract
I have described several methodologies useful for detecting protein solubility,
interactions, and glycosylation in the periplasm. The applications of these meth-
ods to protein engineering have been demonstrated in some cases (e.g., the en-
gineering of more soluble Amyloid β peptides explained in Chapter 2). This
chapter will expand on these tools and propose experiments that could lead to
further applications for protein and glycosylation engineering in E. coli.
Glycosylation of a eukaryotic protein
We sought to determine if a eukaryotic glycoprotein, RNAse, would be glyco-
sylated in the context of a C-terminal TEM-1 β-lactamase fusion, as in Chapter
3. We cloned the gene encoding bovine RNAse A, the aglycosylated form, into
the pDMB reporter system. A point mutation had been previously introduced
into this gene to incorporate an S32D mutation[128]. This mutation allowed the
amino acid sequence to correspond to the known C. jejuni consensus glycosyla-
tion sequence of D/E-X1-N-X2-S/T [129].
RNAse A has been shown in literature to be more stable when glycosylated.
Arnold et al. showed that glycosylated RNAse A was more resistant to protease
degradation, had significantly slower rate constants, and had a 1.5◦C higher
melting temperature compared to the aglycosylated form [5]. Molecular dy-
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namics studies of the protein have shown that glycosylation destabilizes the
unfolded state via the formation of hydrogen bonds during the unfolding pro-
cess. The same study also predicted that glycosylation adds 2.5 kJ/mol to the
overall protein stability [42]. We reasoned that this increase in stability due to
glycosylation could translate to increased growth on ampicillin in the context of
a BLA fusion, as we had previously seen in the case of Peb3 (Chapter 3).
We co-transformed the plasmid expressing the RNAse-BLA fusion with ei-
ther pglKan or pglmutKan (see Chapter 3 for descriptions). Spot plating on
ampicillin revealed no change in overall growth phenotype due to glycosyla-
tion (Figure 6.1a). A nitrocefin hydrolysis assay for BLA activity also showed no
significant difference (Figure 6.1c). We hypothesized that that glycosylation of
this eukaryotic protein was inefficient. Indeed, the glycosylation site of RNAse
lies in a highly structured region [128] which is difficult to glycosylate using the
enzymes of the C. jejuni pathway.
Western blotting confirmed that RNAse is glycosylated in the context of an
RNAse-BLA fusion (Figure 6.1b). To our knowledge, this is the first instance
of soluble production of glycosylated RNAse A in E. coli. However, the effi-
ciency of glycosylation was not apparent from the blot. Further experiments are
needed to determine the actual glycosylation efficiency. Nitrocefin hydrolysis
assay for BLA activity also showed no significant difference (Figure 6.1c).
We next sought to determine whether cotranslational translocation con-
tributed to our ability to glycosylate this protein, as the DsbA signal sequence
that is N-terminal to the fusion has been shown to co-translationally translocate
proteins [199]. To test this hypothesis, we made fusions of the signal sequences
of PhoA, MalE, and DsbA to RNaseA. The ssPhoA and ssMalE are directed
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Figure 6.1: Analysis of RNAse A-BLA fusions. (a) Spot plating as in Figure 3 on
200 µg/mL Amp and 50 µg/mL Kan (b) Western blot analysis as in Figure 3 (c)
Nitrocefin hydrolysis activity as in Figure 3. (d) Western blotting with hR6 of
RNAseA (no BLA fusion) fused to N-terminal signal sequences of DsbA, MalE,
and PhoA.
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through the Sec pathway, with ssMalE export being dependent on SecB [135]
and ssPhoA export independent of SecB [134]. Western blotting of the signal
sequence-RNAseA S32D fusions showed that glycosylation occurred in all three
cases. This implies that co-translational translocation may not affect the overall
efficiency of glycosylation in the case of this particular protein.
Materials and Methods
The gene for RNAseA S32D was amplified from the plasmid pMIK81, gener-
ously provided by Markus Aebi [128]. For solubility studies, RNAse was cloned
between the SfiI sites of pDMB (as described in Chapter 3). For signal sequence
studies, plasmids based on pTrc99A containing the ssPhoA, ssMalE, and ss-
DsbA signal sequences were used as backbone [72] and RNAseA was cloned
between XbaI and HindIII sites in these plasmids. A FLAG tag was appended
to RNAse A 3’ of the HindIII site and stop codon for immunodetection. Spot
plating, Western blotting, and nitrocefin assays were performed as described in
Chapter 3.
Engineering glycosylation in E. coli
The methodology described in Chapter 3, a reporter of protein glycosylation,
has obvious applications for directed evolution and glycoengineering. Using
the ampicillin resistance phenotype as a reporter, one could imagine perform-
ing selections (1) for functional glycosylation machinery and (2) for improved
glycosylation machinery. For example, the method could be used to study
the efficiency of glycosylation of multiple oligosyltransferases (OSTs) by sim-
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ply cloning families of monomeric OSTs in place of the C. jejuni PglB. The high
throughput of this method would allow preliminary characterization of many
OSTs in a single round of plating on ampicillin.
Next, directed evolution via colony PCR, DNA shuffling, or any other com-
parable method of library creation could be undertaken on the C. jejuni pgl sys-
tem to improve the overall rate of glycosylation. In this system, protein glyco-
sylation is likely not at its peak efficiency and as such improved glycosylation in
proteins whose solubility is sensitive to sugar attachment (e.g., Peb3, CjaA, and
engineered im7 peptides) could lead to increased growth on ampicillin. Those
sets of engineered machinery proteins which lead to higher growth on ampicllin
could then be further characterized.
Finally, as mentioned in Chapter 4, pathways inherent to E. coli metabolism
could be manipulated to affect glycosylation efficiency. By screening knock-
out strains (or libraries of knockouts such as the Keio collection [7]) or libraries
created by such strain engineering methods as MAGE [242] or TRMR [246], it
could be possible to isolate genetic elements of bacterial cells that contribute
to glycosylation and use this information to optimize the overall production of
glycoproteins.
A reporter of protein-carbohydrate interactions
To our knowledge, there exists no method of reporting the interactions between
proteins and carbohydrates in vivo. Combining some of the tools developed in
this work could lead to the creation of such a reporter. A method of reporting
specific protein-carbohydrate interactions would be useful in many ways. First,
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Figure 6.2: Schematic of the protein-carbohydrate interaction complementation
assay. Binding of a sugar group by a carbohydrate binding protin results in
formation of an active BLA complex which is able to hydrolyze ampicilin, con-
ferring an antibiotic-resistance phenotype.
it could provide rapid, direct evidence of glycosylation as opposed to the indi-
rect method of glycosylation reporting (via a change in folding and solubility)
detailed in Chapter 3. Second, by designing a reporter to interact with specific
glycans, the reporter could be used for engineering of these glycans. Third, the
method could be used to evolve novel or more specific protein-carbohydrate
interactions.
Figure 6.2 shows a schematic of how such a protein-carbohydrate reporter
might operate in E. coli. A carbohydrate binding domain (CBD) (e.g., a lectin
or glycan-specific antibody) is fused to an inactive split fragment of TEM-1 β-
lactamase, much in the same manner as described in Chapter 5. The second
split fragment of BLA is fused to a target glycoprotein. When this target protein
is glycosylated with sugars to which the CBD has some affinity, the binding of
the CBD and glycan would complement BLA activity. Selection for this binding
activity can be accomplished by plating on ampicllin or other β-lactam antibi-
otics.
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Conclusions
We have presented tools that will help us to better understand and engineer the
environment of the E. coli periplasm. Protein folding, solubility, interactions,
and post-translational modifications in this compartment are required for the
economical production of many therapeutic proteins in E. coli. Specifically, the
methods presented in this work have laid the groundwork for engineering of
glycoprotein production in E. coli. Further experiments (explained above) could
lead to specific engineering of cellular glycan structure and improvement of
carbohydrate-binding domains. In the end, gaining understanding of the com-
plex processes of protein translocation, folding, and post-translational modifi-
cations in the periplasm is critical to solving an array of biotechnological prob-
lems and further expands the role of the well-understood workhorse organism
Escherichia coli.
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